

# BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
30 May 2002 (30.05.2002)

PCT

(10) International Publication Number  
WO 02/42445 A2

(51) International Patent Classification<sup>7</sup>: C12N 15/00 (72) Inventors; and  
 (21) International Application Number: PCT/US01/44309 (75) Inventors/Applicants (for US only): GOLD, Joseph, D. [US/US]; 100 Lundy's Lane, San Francisco, CA 94110 (US). LEBROWSKI, Jane, S. [US/US]; 150 Gabarda Way, Portola Valley, CA 94028 (US).

(22) International Filing Date: 26 November 2001 (26.11.2001) (74) Agent: SCHIFF, J., Michael; Geron Corporation, 230 Constitution Drive, Menlo Park, CA 94025 (US).

(25) Filing Language: English (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.


(26) Publication Language: English (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

(30) Priority Data:  
 60/253,443 27 November 2000 (27.11.2000) US  
 60/253,357 27 November 2000 (27.11.2000) US  
 09/783,203 13 February 2001 (13.02.2001) US


(71) Applicant (for all designated States except US): GERON CORPORATION [US/US]; 230 Constitution Drive, Menlo Park, CA 94025 (US). (73) Patent Cooperation Treaty (PCT) Application Data: (76) International Application Number: PCT/US01/44309 (77) International Filing Date: 26 November 2001 (26.11.2001) (78) International Publication Date: 30 May 2002 (30.05.2002) (79) International Publication Number: WO 02/42445 A2 (80) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: DIFFERENTIATED CELLS SUITABLE FOR HUMAN THERAPY



(57) Abstract: This invention provides a system for producing differentiated cells from a stem cell population for use wherever a relatively homogenous cell population is desirable. The cells contain an effector gene under control of a transcriptional control element (such as the TERT promoter) that causes the gene to be expressed in relatively undifferentiated cells in the population. Expression of the effector gene results in depletion of undifferentiated cells, or expression of a marker that can be used to remove them later. Suitable effector sequences encode a toxin, a protein that induces apoptosis, a cell-surface antigen, or an enzyme (such as thymidine kinase) that converts a prodrug into a substance that is lethal to the cell. The differentiated cell populations produced according to this disclosure are suitable for use in tissue regeneration, and non-therapeutic applications such as drug screening.





Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

- *without international search report and to be republished upon receipt of that report*

**DIFFERENTIATED CELLS  
SUITABLE FOR HUMAN THERAPY**

5

**TECHNICAL FIELD**

This invention relates generally to the field of cell biology of embryonic cells, and the molecular biology of promoter controlled viral vectors. More specifically, it describes a technology for removing undifferentiated cells from populations derived from pluripotent stem cells using selectively expressed lytic vectors.

10

**REFERENCE TO RELATED APPLICATIONS**

This application claims priority to U.S. Patent Applications 60/253,443 and 60/253,357, filed November 27, 2000, pending; and 09/783,203, filed February 13, 2001, pending. For purposes of prosecution of this 15 application in the U.S., the priority documents are hereby incorporated herein by reference in their entirety.

**BACKGROUND**

Precursor cells have become a central interest in medical research. Many tissues in the body have a 20 back-up reservoir of precursors that can replace cells that are senescent or damaged by injury or disease. Considerable effort has been made recently to isolate precursors of a number of different tissues for use in regenerative medicine.

U.S. Patent 5,750,397 (Tsukamoto et al., Systemix) reports isolation and growth of human hematopoietic stem cells which are Thy-1+, CD34+, and capable of differentiation into lymphoid, erythroid, and 25 myelomonocytic lineages. U.S. Patent 5,736,396 (Bruder et al.) reports methods for lineage-directed differentiation of isolated human mesenchymal stem cells, using an appropriate bioactive factor. The derived cells can then be introduced into a host for mesenchymal tissue regeneration or repair.

U.S. Patent 5,716,411 (Orgill et al.) proposes regenerating skin at the site of a burn or wound, using an epithelial autograft. U.S. Patent 5,766,948 (F. Gage) reports a method for producing neuroblasts from 30 animal brain tissue. U.S. Patent 5,672,499 (Anderson et al.) reports obtaining neural crest stem cells from embryonic tissue. U.S. Patent 5,851,832 (Weiss et al., Neurospheres) reports isolation of putative neural stem cells from 8-12 week old human fetuses. U.S. Patent 5,968,829 (M. Carpenter) reports human neural stem cells derived from primary central nervous system tissue.

U.S. Patent 5,082,670 (F. Gage) reports a method for grafting genetically modified cells to treat 35 defects, disease or damage of the central nervous system. Auerbach et al. (Eur. J. Neurosci. 12:1696, 2000) report that multipotential CNS cells implanted into animal brains form electrically active and functionally connected neurons. Brustle et al. (Science 285:754, 1999) report that precursor cells derived from embryonic stem cells interact with host neurons and efficiently myelinate axons in the brain and spinal cord.

Considerable interest has been generated by the development of embryonic stem cells, which are 40 thought to have the potential to differentiate into many cell types. Early work on embryonic stem cells was done in mice. Mouse stem cells can be isolated from both early embryonic cells and germinal tissue. Desirable characteristics of pluripotent stem cells are that they be capable of proliferation in vitro in an undifferentiated state, retain a normal karyotype, and retain the potential to differentiate to derivatives of all three embryonic germ layers (endoderm, mesoderm, and ectoderm).

Development of human pluripotent stem cell preparations is considerably less advanced than work with mouse cells. Thomson et al. propagated pluripotent stem cells from lower primates (U.S. Patent 5,843,780; Proc. Natl. Acad. Sci. USA 92:7844, 1995), and then from humans (Science 282:114, 1998). Gearhart and coworkers derived human embryonic germ (hEG) cell lines from fetal gonadal tissue (Shambrott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998; and U.S. Patent 6,090,622).

5 Both hES and hEG cells have the long-sought characteristics of pluripotent stem cells: they are capable of being grown *in vitro* without differentiating, they have a normal karyotype, and they remain capable of producing a number of different cell types. Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods in culture (Amit et al., Dev. Biol. 227:271, 2000).

10 These cells hold considerable promise for use in human therapy, acting as a reservoir for regeneration of almost any tissue compromised by genetic abnormality, trauma, or a disease condition.

15 International Patent Publication WO 99/20741 (Geron Corp.) refers to methods and materials for growing primate-derived primordial stem cells. In one embodiment, a cell culture medium is provided for growing primate-derived primordial stem cells in a substantially undifferentiated state, having a low osmotic pressure and low endotoxin levels. The basic medium is combined with a nutrient serum effective to support the growth of primate-derived primordial stem cells and a substrate of feeder cells or an extracellular matrix component derived from feeder cells. The medium can further include non-essential amino acids, an anti-oxidant, and growth factors that are either nucleosides or a pyruvate salt.

20 A significant challenge to the use of stem cells for therapy is to control growth and differentiation into the particular type of tissue required for treatment of each patient.

25 U.S. Patent 4,959,313 (M. Taketo, Jackson Labs) provides a particular enhancer sequence that causes expression of a flanking exogenous or recombinant gene from a promoter accompanying the gene that does not normally cause expression in undifferentiated cells. U.S. Patent 5,639,618 (D.A. Gay, Plurion Inc.) proposes a method for isolating a lineage specific stem cell *in vitro*, in which a pluripotent embryonic stem cell is transfected with a construct in which a lineage-specific genetic element is operably linked to a reporter gene, culturing the cell under conditions where the cell differentiates, and then separation of cells expressing the reporter are separated from other cells.

30 U.S. Patent 6,087,168 (Levesque et. al., Cedars Sinai Med. Ctr.) is directed to transdifferentiating epidermal cells into viable neurons useful for both cell therapy and gene therapy. Skin cells are transfected with a neurogenic transcription factor, and cultured in a medium containing an antisense oligonucleotide corresponding to a negative regulator of neuronal differentiation.

35 International Patent Publication WO 97/32025 (McIvor et al., U. Minnesota) proposes a method for engrafting drug resistant hematopoietic stem cells. The cells in the graft are augmented by a drug resistance gene (such as methotrexate resistant dihydrofolate reductase), under control of a promoter functional in stem cells. The cells are administered into a mammal, which is then treated with the drug to increase engraftment of transgenic cells relative to nontransgenic cells.

40 International Patent Publication WO 98/39427 (Stein et al., U. Massachusetts) refers to methods for expressing exogenous genes in differentiated cells such as skeletal tissue. Stem cells (e.g., from bone marrow) are contacted with a nucleic acid in which the gene is linked to an element that controls expression in differentiated cells. Exemplary is the rat osteocalcin promoter. International Patent Publication WO 99/10535 (Liu et al., Yale U.) proposes a process for studying changes in gene expression in stem cells. A gene expression profile of a stem cell population is prepared, and then compared a gene expression profile of differentiated cells

International Patent Publication WO 99/19469 (Braetscher et al., Biotransplant) refers to a method for growing pluripotent embryonic stem cells from the pig. A selectable marker gene is inserted into the cells so as to be regulated by a control or promoter sequence in the ES cells, exemplified by the porcine OCT-4 promoter.

5 International Patent Publication WO 00/15764 (Smith et al., U. Edinburgh) refers to propagation and derivation of embryonic stem cells. The cells are cultured in the presence of a compound that selectively inhibits propagation or survival of cells other than ES cells by inhibiting a signaling pathway essential for the differentiated cells to propagate. Exemplary are compounds that inhibit SHP-2, MEK, or the ras/MAPK cascade.

10 Klug et al. (J. Clin. Invest. 98:216, 1996) propose a strategy for genetically selecting cardiomyocytes from differentiating mouse embryonic stem cells. A fusion gene consisting of the  $\alpha$ -cardiac myosin heavy chain promoter and a cDNA encoding aminoglycoside phosphotransferase was stably transfected into the ES cells. The resulting lines were differentiated in vitro and selected using G418. The selected cardiomyocyte cultures were reported to be highly differentiated. When engrafted back into mice, ES-derived cardiomyocyte grafts were detectable as long as 7 weeks after implantation.

15 Schuldiner et al. (Proc. Natl. Acad. Sci. USA 97:11307, 2000) report the effects of eight growth factors on the differentiation of cells from human embryonic stem cells. After initiating differentiation through embryoid body formation, the cells were cultured in the presence of bFGF, TGF- $\beta$ 1, activin-A, BMP-4, HGF, EGF,  $\beta$ NGF, or retinoic acid. Each growth factor had a unique effect on the differentiation pathway, but none of the growth factors directed differentiation exclusively to one cell type.

20 There is a need for new approaches to generate populations of differentiated cells suitable for human administration.

#### SUMMARY OF THE INVENTION

25 This invention provides a system for depleting relatively undifferentiated cells from a heterogeneous cell population, such as may be obtained by differentiation of stem cells. The population is treated with a vector that puts a lethal or potentially lethal effector gene under control of a gene element that allows the gene to be expressed at a higher level in the undifferentiated subpopulation. This produces a population relatively enriched for mature cells, and suitable for use in regenerative medicine.

30 One embodiment of this invention is a population of cells differentiated from stem cells cultured *ex vivo*, which is essentially free of undifferentiated cells. Exemplary are pluripotent stem cells of primate origin, such as human embryonic stem cells.

35 Cells in the population can contain or be derived using a polynucleotide comprising the structure P-X, where X is a nucleic acid sequence that is lethal to a cell in which it is expressed, or renders a cell in which it is expressed susceptible to a lethal effect of an external agent; and P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells. The connecting line in P-X indicates that the genetic elements are operatively linked, whether or not they are adjacent in the nucleic acid molecule.

40 X is referred to in the description that follows as an effector sequence. X can encode a toxin, a protein that induces or mediates apoptosis, or an enzyme (such as thymidine kinase) that converts a prodrug (such as ganciclovir) to a compound that is lethal to a cell in which X is expressed. Other examples are provided later in this disclosure.

In certain embodiments, P-X is an introduced heterologous molecule, meaning that the cell or its ancestors was genetically altered with a vector comprising P-X. In other embodiments the cell or its ancestors was genetically altered with a vector to place X under control of an endogenous transcriptional control element.

Following transfection, X can be either transiently expressed in undifferentiated cells in the population, or P-X can be inheritable and expressed in undifferentiated progeny. Non-limiting examples for P include the OCT-4 promoter, and the promoter of telomerase reverse transcriptase (TERT). The cells can also contain a drug resistance gene Y under control of P, depicted in this disclosure as P-X-Y, indicating a functional relationship 5 where P regulates transcription of both X and Y, with the elements being in any orientation in the sequence that links the functions in this manner.

Another embodiment of the invention is a stem cell genetically altered so as to contain a nucleic acid with the structure P-X, as already described. The invention also provides polynucleotide vectors adapted to genetically alter stem cells in this fashion.

10 Another embodiment of the invention is a method of producing a population of differentiated cells. A cell population comprising undifferentiated stem cells that contain a nucleic acid molecule comprising the structure P-X is treated to cause at least some undifferentiated cells in the population to differentiate.

15 Another embodiment of the invention is a method for depleting undifferentiated stem cells from a cell population. Stem cells in the population are genetically altered so that they contain a nucleic acid molecule comprising the structure P-X as already described. In this way, a gene that is lethal to a cell in which it is expressed, or renders it susceptible to a lethal effect of an external agent, is placed under control of a transcriptional control element that causes the gene to be preferentially expressed in undifferentiated cells. The cell population can be genetically altered when it is still predominantly undifferentiated (before being caused to differentiate), or when it already predominantly comprises differentiated cells.

20 If X is lethal to the cell, then undifferentiated stem cells can be depleted simply by culturing the cell population under conditions where X is expressed. If X renders the cell susceptible to lethal effects of an external agent (such as a drug or prodrug), then undifferentiated stem cells are depleted by combining the cells with the external agent. This can be done by contacting the cells in vitro with the agent in tissue culture, or administering the cells to the subject simultaneously or sequentially with the external agent, if not already 25 present.

The reagents and techniques of this invention can be brought to bear on cell populations containing any type of stem cells. They are especially suited for application to primate pluripotent stem cells, such as human embryonic stem cells.

Other embodiments of the invention will be apparent from the description that follows.

30

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides an analysis of OCT-4 and hTERT expression in hES cells cultured with feeder cells (mEF) or extracellular matrix (Matrigel® or laminin) with regular medium (RM) or conditioned medium (CM). 35 The upper panel is a copy of a gel showing OCT-4 and hTERT expression at the mRNA level by RT-PCR. The lower panel is a bar graph comparing the level of expression for cells grown on different substrates, expressed as the ratio of OCT-4 or hTERT to the 18s standard. hES cells grown on Laminin and Matrigel® in conditioned medium have similar expression patterns to those of cells grown on a feeder layer.

Figure 2 is a half-tone reproduction of a gel showing telomerase activity measured in cultured hES 40 cells by TRAP activity assay. All the culture conditions showed positive telomerase activity after 40 days in feeder-free culture.

Figure 3 is a half-tone reproduction showing expression of the GFP reporter gene in hES cells transduced with retrovirus and then differentiated. hES cells were transferred to suspension culture to form embryoid bodies, cultured for a further 4 days, replated onto gelatin-coated slides and cultured for a week, and

then fixed and photographed under fluorescence for GFP expression. Left panels show bright-field illumination; right panels show fluorescence due to GFP expression.

Figure 4 shows the results of a study in which hES cells were transiently genetically altered in feeder-free culture by lipofection. Panel A is a half-tone reproduction of a light micrograph showing morphology of hES cells on laminin after they have been transfected. Panel B is a half-tone reproduction of a fluorescence micrograph showing GFP expression in the same colony. Panel C is a bar graph showing percentage of cells expressing GFP under various conditions.

Figure 5 is a map of TPAC vector designated pGRN376. This is an adenovirus vector of 7185 bp comprising the herpes simplex thymidine kinase (*tk*) gene under control of a promoter taken from the upstream sequence of the human gene for telomerase reverse transcriptase (hTERT). Expression of *tk* is promoted in cells expressing hTERT, such as undifferentiated embryonic stem cells.

Figure 6 is a two-panel line graph, showing the effect of the TPAC thymidine kinase vector on undifferentiated hES cells. 48 h after replating, the cells were transduced with TPAC vector at an MOI of 30 or 100, or mock transduced (no vector added). Four h later, the cells were exchanged into fresh medium containing the prodrug ganciclovir (GCV). By day 3, wells treated with TPAC vector + GCV contained 8% as many cells as the control wells.

Figure 7 is a bar graph showing titration of GCV in TPAC vector treated hES cells. 4 h after transduction with the vector, fresh medium was added containing GCV at the concentration shown. ~20  $\mu$ M GCV was optimal under the conditions tested.

Figure 8 is a two-panel bar graph showing titration of GCV on TPAC vector transduced and mock-transduced hES cells from two different lines. Both lines are sensitive to GCV after treatment with the TPAC vector.

Figure 9 shows the effect of TPAC + GCV treatment on mixed cell populations obtained from differentiation of hES cells. The cells were fed daily with conditioned medium to maintain the undifferentiated state, or with either 500 nM retinoic acid or 0.5% DMSO, to induce differentiation into committed cells of mixed phenotype. 7 days later, they were infected with the TPAC vector at an MOI of 30, plus 20  $\mu$ M GCV.

The Upper Panel is a bar graph showing the number of cells surviving in culture. Treatment with TPAC + GCV eliminated cells cultured under each condition. In each instance, culture of the surviving cells produced populations that appeared highly differentiated and substantially free of undifferentiated morphology. The Lower Panel is a half-tone reproduction of a gel showing RT-PCR analysis of the surviving cells. Those cells cultured with conditioned medium (mEF-CM) or DMSO had no detectable OCT-4 expression, while 2 out of 4 samples treated with retinoic acid (RA) showed amplification products consistent with very low levels of OCT-4 expression.

Figure 10 is a reproduced micrograph of an hES cell line that has been transduced by combining with a control adenovirus vector (Panel A), or pGRN376 (Panel B), which contains the *tk* gene under control of the TERT promoter. Both wells of transduced cells were cultured for 3 days in a medium containing ganciclovir. Undifferentiated colonies typical of normal hES cell cultures were seen in the control wells. In the wells treated with pGRN376, most or all undifferentiated ES cell colonies were gone, and only differentiated cells remained.

Figure 11 is a two-panel line graph, showing drug sensitivity of undifferentiated cells containing the telomerase promoter driven thymidine kinase gene (TPAC). Upper and lower panels show sensitivity to the prodrugs ganciclovir (GCV) and (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), respectively. Ganciclovir at a concentration as low as 2.5  $\mu$ M kills virtually all of the undifferentiated TPAC ES cells within ~4 days.

Figure 12(A) and (B) comprises black-and-white reproductions of fluorescence micrographs of differentiated ES cells. Cell lines H9-376m-18, H9-376m-62, and H9-376m-6 contain the TPAC gene; H9-pGK-

neo-1 is the control cell line transfected only with the drug selection plasmid. The stably transfected cells were differentiated into embryoid bodies, and plated for immunocytochemistry analysis. At least three of the TPAC containing stem cell lines show areas that stain for muscle specific actin,  $\alpha$ -fetoprotein,  $\beta$ -tubulin, and cardiac troponin I, representative of all three embryonic germ layers.

5

DETAILED DESCRIPTION OF THE INVENTION

10 Stem cells of various kinds have become an extremely attractive modality in regenerative medicine. They can be proliferated in culture, and then differentiated *in vitro* or *in situ* into the cell types needed for therapy. Recently, it has been demonstrated that human embryonic stem cells continuously express a high level of telomerase, enabling them to maintain telomere length and grow almost indefinitely in culture.

15 So far, efforts to differentiate stem cells have been directed primarily towards identifying culture conditions that promote outgrowth of a cell population with phenotypic features of a tissue type desirable for regenerative medicine. Schuldiner et al. (*supra*) report the effects of growth factors on the differentiation of human embryonic stem cells. In U.S. Patent 5,639,613, stem cells are transfected with a lineage-specific gene that is operably linked to a reporter gene, which is then used to select for cells expressing the reporter. In WO 97/32025, hematopoietic stem cells are augmented by a drug resistance gene, and then engrafted into a subject. The cells are administered into a mammal, which is then treated with the drug to increase engraftment of transgenic cells. Klug et al. (*supra*) used a construct in which the  $\alpha$ -cardiac myosin heavy chain promoter controlled expression of aminoglycoside phosphotransferase. Transfected differentiated cells were selected using G418, which produced lines of cardiomyocyte like cells. This is a positive selection strategy that uses gene expression patterns of the desired tissue type to allow preferential survival of differentiated tissue.

20 25 It is a hypothesis of this invention that some of the populations of differentiated cells produced using adaptive culture and positive selection methods will be suboptimal for use in human therapy. In some circumstances, undifferentiated cells in the population may impair engraftment or function of the cells *in vivo*. Undifferentiated cells may also increase the possibility of a malignancy or other tumor forming at the site of the therapeutic implant, or by migration of transplanted cells.

30 35 This invention is directed towards a strategy in which undifferentiated cells remaining in such differentiated cell populations can be depleted. This is effected by genetically altering the cells, so that a gene that is lethal to a cell in which it is expressed, or renders it susceptible to a lethal effect of an external agent, is placed under transcriptional control of a genetic element that causes it to be expressed preferentially in any undifferentiated cells in the population. This is a negative selection strategy, designed to minimize the proportion of undifferentiated cells. It is possible to combine this technique with positive selection techniques of various kinds, in order to obtain relatively pure populations of the desired tissue type that are essentially free of undifferentiated cells.

40 As a non-limiting validation of the invention, human embryonic stem (hES) cells have been transduced with an adenovirus vector (TPAC) in which a herpes virus thymidine kinase gene was placed under control of a promoter sequence for human telomerase reverse transcriptase (hTERT). hES cells constitutively express hTERT, but this ability is lost upon differentiation. Example 10 (Figures 6-8) show that transduction of hES cells with TPAC vector renders undifferentiated cells susceptible to lethality by the prodrug ganciclovir, a substrate for thymidine kinase, at a concentration of ~ 20  $\mu$ M. Example 11 (Figure 9) shows that when hES cells are transduced with TPAC vector and then differentiated with DMSO, there are no surviving cells with detectable OCT-4 expression (a phenotype of undifferentiated cells).

The techniques of this invention are designed in part to provide cell populations with improved characteristics for human therapy. After depleting undifferentiated cells, the differentiated population is expected to possess better functional and engraftment characteristics, and have reduced risk of creating unwanted tissue architecture and malignancies in the treated subject. In addition, cell populations depleted of undifferentiated cells are more homogeneous, which provides a distinct advantage for non-therapeutic applications, such as producing antibody, cDNA libraries, and screening drug candidates.

Definitions

Prototype "primate Pluripotent Stem cells" (pPS cells) are pluripotent cells derived from pre-embryonic, 10 embryonic, or fetal tissue at any time after fertilization, and have the characteristic of being capable under appropriate conditions of producing progeny of several different cell types that are derivatives of all of the three germinal layers (endoderm, mesoderm, and ectoderm), according to a standard art-accepted test, such as the ability to form a teratoma in 8-12 week old SCID mice.

Included in the definition of pPS cells are embryonic cells of various types, exemplified by human 15 embryonic stem (hES) cells, described by Thomson et al. (Science 282:1145, 1998); embryonic stem cells from other primates, such as Rhesus stem cells (Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995), marmoset stem cells (Thomson et al., Biol. Reprod. 55:254, 1996) and human embryonic germ (hEG) cells (Shambrook et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998). Other types of pluripotent cells are also included 20 in the term. Any cells of primate origin that are capable of producing progeny that are derivatives of all three germinal layers are included, regardless of whether they were derived from embryonic tissue, fetal tissue, or other sources. This invention relates to pPS cells that are not derived from a malignant source. It is desirable (but not always necessary) that the cells be karyotypically normal.

pPS cell cultures are described as "undifferentiated" when a substantial proportion of stem cells and 25 their derivatives in the population display morphological characteristics of undifferentiated cells, clearly distinguishing them from differentiated cells of embryo or adult origin. Undifferentiated pPS cells are easily recognized by those skilled in the art, and typically appear in the two dimensions of a microscopic view in colonies of cells with high nuclear/cytoplasmic ratios and prominent nucleoli. It is understood that colonies of undifferentiated cells within the population will often be surrounded by neighboring cells that are differentiated. Nevertheless, the undifferentiated colonies persist when the population is cultured or passaged under 30 appropriate conditions, and individual undifferentiated cells constitute a substantial proportion of the cell population. Cultures that are substantially undifferentiated contain at least 20% undifferentiated pPS cells, and may contain at least 40%, 60%, or 80% in order of increasing preference. Whenever a culture or cell population is referred to in this disclosure as proliferating "without differentiation", what is meant is that after proliferation, the composition is substantially undifferentiated according to the preceding definition.

35 "Feeder cells" or "feeders" are terms used to describe cells of one type that are co-cultured with cells of another type, to provide an environment in which the cells of the second type can grow. The feeder cells are optionally from a different species as the cells they are supporting. For example, certain types of pPS cells can be supported by primary mouse embryonic fibroblasts, immortalized mouse embryonic fibroblasts, or human fibroblast-like cells differentiated from hES cells, as described later in this disclosure. pPS cell populations are 40 said to be "essentially free" of feeder cells if the cells have been grown through at least one round after splitting in which fresh feeder cells are not added to support the growth of the pPS. Cultures essentially free of feeder cells contain less than about 5% feeder cells. Whenever a culture or cell population is referred to in this

disclosure as "feeder-free", what is meant is that the composition is essentially free of feeder cells according to the preceding definition, subject only to further constraints explicitly required.

5 The term "embryoid bodies" is a term of art synonymous with "aggregate bodies". The terms refer to aggregates of differentiated and undifferentiated cells that appear when pPS cells overgrow in monolayer cultures, or are maintained in suspension cultures. Embryoid bodies are a mixture of different cell types, typically from several germ layers, distinguishable by morphological criteria.

10 The terms "committed precursor cells", "lineage restricted precursor cells" and "restricted developmental lineage cells" all refer to cells that are capable of proliferating and differentiating into several different cell types, with a range that is typically more limited than pluripotent stem cells of embryonic origin capable of giving rise to progeny of all three germ layers. Non-limiting examples of committed precursor cells include hematopoietic cells, which are pluripotent for various blood cells; hepatocyte progenitors, which are pluripotent for bile duct epithelial cells and hepatocytes; and mesenchymal stem cells. Another example is neural restricted cells, which can generate glial cell precursors that progress to oligodendrocytes and astrocytes, and neuronal precursors that progress to neurons.

15 For the purposes of this description, the term "stem cell" can refer to either a pluripotent stem cell, or a committed precursor cell, both as defined above. Minimally, a stem cell has the ability to proliferate and form cells of more than one different phenotype, and is also capable of self renewal — either as part of the same culture, or when cultured under different conditions. Embryonic stem cells can be identified as positive for the enzyme telomerase.

20 As used in this disclosure, "differentiated" and "undifferentiated" are relative terms depending on the context in which they are used. Specifically, in reference to a particular type of self-renewing stem cell, the term "undifferentiated" refers back to the same self-renewing stem cell, whereas the term "differentiated" refers to one or more of the relatively mature phenotypes the stem cell can generate — as discernable by morphological criteria, antigenic markers, and gene transcripts they produce. Undifferentiated pPS cells have 25 the ability to differentiate into all three germ layers. The cells differentiated from them do not, and can readily be recognized by one skilled in the art by morphological criteria.

25 The terms "polynucleotide" and "nucleic acid molecule" refer to a polymer of nucleotides of any length. Included are genes and gene fragments, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA and RNA, nucleic acid probes, and primers. As 30 used in this disclosure, the term polynucleotides refer interchangeably to double- and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention that is a polynucleotide encompasses both a double-stranded form, and each of the two complementary single-stranded forms known or predicted to make up the double-stranded form. Included are nucleic acid analogs such as phosphoramidates and thiophosphoramidates.

35 A cell is said to be "genetically altered", "transfected", or "genetically transformed" when a polynucleotide has been transferred into the cell by any suitable means of artificial manipulation, or where the cell is a progeny of the originally altered cell that has inherited the polynucleotide. The polynucleotide will often comprise a transcribable sequence encoding a protein of interest, which enables the cell to express the protein at an elevated level. The genetic alteration is said to be "inheritable" if progeny of the altered cell have the 40 same alteration.

40 A "control element" or "control sequence" is a nucleotide sequence involved in an interaction of molecules that contributes to the functional regulation of a polynucleotide, such as replication, duplication, transcription, splicing, translation, or degradation of the polynucleotide. Transcriptional control elements include promoters, enhancers, and repressors.

Particular gene sequences referred to as promoters, like the "TERT promoter", or the "OCT-4 promoter", are polynucleotide sequences derived from the gene referred to that promote transcription of an operatively linked gene expression product. It is recognized that various portions of the upstream and intron untranslated gene sequence may in some instances contribute to promoter activity, and that all or any subset of 5 these portions may be present in the genetically engineered construct referred to. The promoter may be based on the gene sequence of any species having the gene, unless explicitly restricted, and may incorporate any additions, substitutions or deletions desirable, as long as the ability to promote transcription in the target tissue. Genetic constructs designed for treatment of humans typically comprise a segment that is at least 90% identical to a promoter sequence of a human gene. A particular sequence can be tested for activity and specificity, for 10 example, by operatively linking to a reporter gene (Example 9).

Genetic elements are said to be "operatively linked" if they are in a structural relationship permitting them to operate in a manner according to their expected function. For instance, if a promoter helps initiate transcription of the coding sequence, the coding sequence can be referred to as operatively linked to (or under control of) the promoter. There may be intervening sequence between the promoter and coding region so long 15 as this functional relationship is maintained.

In the context of encoding sequences, promoters, and other genetic elements, the term "heterologous" indicates that the element is derived from a genetically distinct entity from that of the rest of the entity to which it is being compared. For example, a promoter or gene introduced by genetic engineering techniques into an animal of a different species is said to be a heterologous polynucleotide. An "endogenous" genetic 20 element is an element that is in the same place in the chromosome where it occurs in nature, although other elements may be artificially introduced into a neighboring position.

The terms "polypeptide", "peptide" and "protein" are used interchangeably in this disclosure to refer to polymers of amino acids of any length. The polymer may comprise modified amino acids, it may be linear or branched, and it may be interrupted by non-amino acids.

25

#### General Techniques

For further elaboration of general techniques useful in the practice of this invention, the practitioner can refer to standard textbooks and reviews in cell biology, tissue culture, and embryology. Included are *Teratocarcinomas and embryonic stem cells: A practical approach* (E.J. Robertson, ed., IRL Press Ltd. 1987); 30 *Guide to Techniques in Mouse Development* (P.M. Wasserman et al., eds., Academic Press 1993); *Embryonic Stem Cell Differentiation in Vitro* (M.V. Wiles, Meth. Enzymol. 225:900, 1993); *Properties and uses of Embryonic Stem Cells: Prospects for Application to Human Biology and Gene Therapy* (P.D. Rathjen et al., Reprod. Fertil. Dev. 10:31, 1998). Differentiation of stem cells is reviewed in Robertson, Meth. Cell Biol. 75:173, 1997; and Pedersen, Reprod. Fertil. Dev. 10:31, 1998.

35 Methods in molecular genetics and genetic engineering are described generally in the current editions of *Molecular Cloning: A Laboratory Manual*, (Sambrook et al.); *Oligonucleotide Synthesis* (M.J. Gait, ed.); *Animal Cell Culture* (R.I. Freshney, ed.); *Gene Transfer Vectors for Mammalian Cells* (Miller & Calos, eds.); *Current Protocols in Molecular Biology* and *Short Protocols in Molecular Biology, 3rd Edition* (F.M. Ausubel et al., eds.); and *Recombinant DNA Methodology* (R. Wu ed., Academic Press). Reagents, cloning vectors, and 40 kits for genetic manipulation referred to in this disclosure are available from commercial vendors such as BioRad, Stratagene, Invitrogen, and ClonTech.

General techniques in cell culture and media collection are outlined in *Large Scale Mammalian Cell Culture* (Hu et al., Curr. Opin. Biotechnol. 8:148, 1997); *Serum-free Media* (K. Kitano, Biotechnology 17:73,

1991); *Large Scale Mammalian Cell Culture* (Curr. Opin. Biotechnol. 2:375, 1991); and *Suspension Culture of Mammalian Cells* (Birch et al., Bioprocess Technol. 19:251, 1990). Other observations about the media and their impact on the culture environment have been made by Marshall McLuhan and Fred Allen.

5 Sources of Stem Cells

This invention can be practiced using stem cells of various types, which may include the following non-limiting examples.

10 U.S. Patent 5,851,832 reports multipotent neural stem cells obtained from brain tissue. U.S. Patent 5,766,948 reports producing neuroblasts from newborn cerebral hemispheres. U.S. Patent 5,654,183 and 5,849,553 report the use of mammalian neural crest stem cells. U.S. Patent 6,040,180 reports *in vitro* generation of differentiated neurons from cultures of mammalian multipotential CNS stem cells. WO 98/50526 and WO 99/01159 report generation and isolation of neuroepithelial stem cells, oligodendrocyte-astrocyte precursors, and lineage-restricted neuronal precursors. U.S. Patent 5,968,829 reports neural stem cells obtained from embryonic forebrain and cultured with a medium comprising glucose, transferrin, insulin, 15 selenium, progesterone, and several other growth factors.

20 Primary liver cell cultures can be obtained from human biopsy or surgically excised tissue by perfusion with an appropriate combination of collagenase and hyaluronidase. Alternatively, EP 0 953 633 A1 reports isolating liver cells by preparing minced human liver tissue, resuspending concentrated tissue cells in a growth medium and expanding the cells in culture. The growth medium comprises glucose, insulin, transferrin, T<sub>3</sub>, FCS, and various tissue extracts that allow the hepatocytes to grow without malignant transformation. The cells in the liver are thought to contain specialized cells including liver parenchymal cells, Kupffer cells, sinusoidal 25 endothelium, and bile duct epithelium, and also precursor cells (referred to as "hepatoblasts" or "oval cells") that have the capacity to differentiate into both mature hepatocytes or biliary epithelial cells (L.E. Rogler, Am. J. Pathol. 150:591, 1997; M. Alison, Current Opin. Cell Biol. 10:710, 1998; Lazaro et al., Cancer Res. 58:514, 1998).

30 U.S. Patent 5,192,553 reports methods for isolating human neonatal or fetal hematopoietic stem or progenitor cells. U.S. Patent 5,716,827 reports human hematopoietic cells that are Thy-1 positive progenitors, and appropriate growth media to regenerate them *in vitro*. U.S. Patent 5,635,387 reports a method and device for culturing human hematopoietic cells and their precursors. U.S. Patent 6,015,554 describes a method of 35 reconstituting human lymphoid and dendritic cells.

U.S. Patent 5,486,359 reports homogeneous populations of human mesenchymal stem cells that can differentiate into cells of more than one connective tissue type, such as bone, cartilage, tendon, ligament, and dermis. They are obtained from bone marrow or periosteum. Also reported are culture conditions used to expand mesenchymal stem cells. WO 99/01145 reports human mesenchymal stem cells isolated from 40 peripheral blood of individuals treated with growth factors such as G-CSF or GM-CSF. WO 00/53795 reports adipose-derived stem cells and lattices, substantially free of adipocytes and red cells. These cells reportedly can be expanded and cultured to produce hormones and conditioned culture media.

The invention can be practiced using stem cells of any vertebrate species. Included are stem cells from humans; as well as non-human primates, domestic animals, livestock, and other non-human mammals. 45 Amongst the stem cells suitable for use in this invention are primate pluripotent stem (pPS) cells derived from tissue formed after gestation, such as a blastocyst, or fetal or embryonic tissue taken any time during gestation. Non-limiting examples are primary cultures or established lines of embryonic stem cells.

*Media and Feeder Cells*

Media for isolating and propagating pPS cells can have any of several different formulas, as long as the cells obtained have the desired characteristics, and can be propagated further. Suitable sources are as follows: Dulbecco's modified Eagles medium (DMEM), Gibco # 11965-092; Knockout Dulbecco's modified 5 Eagles medium (KO DMEM), Gibco # 10829-018; 200 mM L-glutamine, Gibco # 15039-027; non-essential amino acid solution, Gibco 11140-050;  $\beta$ -mercaptoethanol, Sigma # M7522; human recombinant basic fibroblast growth factor (bFGF), Gibco # 13256-029. Exemplary serum-containing ES medium is made with 80% DMEM (typically KO DMEM), 20% defined fetal bovine serum (FBS) not heat inactivated, 0.1 mM non-essential amino acids, 1 mM L-glutamine, and 0.1 mM  $\beta$ -mercaptoethanol. The medium is filtered and stored at 10 4°C for no longer than 2 weeks. Serum-free ES medium is made with 80% KO DMEM, 20% serum replacement, 0.1 mM non-essential amino acids, 1 mM L-glutamine, and 0.1 mM  $\beta$ -mercaptoethanol. An effective serum replacement is Gibco # 10828-028. The medium is filtered and stored at 4°C for no longer than 2 weeks. Just before use, human bFGF is added to a final concentration of 4 ng/mL (Bodnar et al., Geron Corp, International Patent Publication WO 99/20741).

15 Feeder cells (where used) are propagated in mEF medium, containing 90% DMEM (Gibco # 11965-092), 10% FBS (Hyclone # 30071-03), and 2 mM glutamine. mEFs are propagated in T150 flasks (Corning # 430825), splitting the cells 1:2 every other day with trypsin, keeping the cells subconfluent. To prepare the feeder cell layer, cells are irradiated at a dose to inhibit proliferation but permit synthesis of 20 important factors that support hES cells (~4000 rads gamma irradiation). Six-well culture plates (such as Falcon # 304) are coated by incubation at 37°C with 1 mL 0.5% gelatin per well overnight, and plated with 375,000 irradiated mEFs per well. Feeder cell layers are typically used 5 h to 4 days after plating. The medium is replaced with fresh hES medium just before seeding pPS cells.

25 Conditions for culturing other stem cells are known, and can be optimized appropriately according to the cell type. Media and culture techniques for particular cell types referred to in the previous section are provided in the references cited.

*Embryonic Stem Cells*

Embryonic stem cells can be isolated from blastocysts of members of the primate species (Thomson et al., Proc. Natl. Acad. Sci. USA 92:7844, 1995). Human embryonic stem (hES) cells can be prepared from 30 human blastocyst cells using the techniques described by Thomson et al. (U.S. Patent 5,843,780; Science 282:1145, 1998; Curr. Top. Dev. Biol. 38:133 ff., 1998) and Reubinoff et al., Nature Biotech. 18:399,2000.

Briefly, human blastocysts are obtained from human in vivo preimplantation embryos. Alternatively, in vitro fertilized (IVF) embryos can be used, or one cell human embryos can be expanded to the blastocyst stage (Bongso et al., Hum Reprod 4: 706, 1989). Human embryos are cultured to the blastocyst stage in G1.2 and 35 G2.2 medium (Gardner et al., Fertil. Steril. 69:84, 1998). Blastocysts that develop are selected for ES cell isolation. The zona pellucida is removed from blastocysts by brief exposure to pronase (Sigma). The inner cell masses are isolated by immunosurgery, in which blastocysts are exposed to a 1:50 dilution of rabbit anti-human spleen cell antiserum for 30 minutes, then washed for 5 minutes three times in DMEM, and exposed to a 1:5 dilution of Guinea pig complement (Gibco) for 3 minutes (see Solter et al., Proc. Natl. Acad. Sci. USA 72:5099, 40 1975). After two further washes in DMEM, lysed trophectoderm cells are removed from the intact inner cell mass (ICM) by gentle pipetting, and the ICM plated on mEF feeder layers.

After 9 to 15 days, inner cell mass-derived outgrowths are dissociated into clumps either by exposure to calcium and magnesium-free phosphate-buffered saline (PBS) with 1 mM EDTA, by exposure to dispase or trypsin, or by mechanical dissociation with a micropipette; and then replated on mEF in fresh medium.

Dissociated cells are replated on mEF feeder layers in fresh ES medium, and observed for colony formation. Colonies demonstrating undifferentiated morphology are individually selected by micropipette, mechanically dissociated into clumps, and replated. ES-like morphology is characterized as compact colonies with apparently high nucleus to cytoplasm ratio and prominent nucleoli. Resulting ES cells are then routinely split 5 every 1-2 weeks by brief trypsinization, exposure to Dulbecco's PBS (without calcium or magnesium and with 2 mM EDTA), exposure to type IV collagenase (~200 U/mL; Gibco) or by selection of individual colonies by micropipette. Clump sizes of about 50 to 100 cells are optimal.

*Embryonic Germ Cells*

10 Human Embryonic Germ (hEG) cells can be prepared from primordial germ cells present in human fetal material taken about 8-11 weeks after the last menstrual period. Suitable preparation methods are described in Shamblott et al., Proc. Natl. Acad. Sci. USA 95:13726, 1998 and U.S. Patent 6,090,622.

Briefly, genital ridges are rinsed with isotonic buffer, then placed into 0.1mL 0.05% trypsin/0.53 mM sodium EDTA solution (BRL) and cut into <1 mm<sup>3</sup> chunks. The tissue is then pipetted through a 100 µL tip to 15 further disaggregate the cells. It is incubated at 37°C for ~5 min, then ~3.5 mL EG growth medium is added. EG growth medium is DMEM, 4500 mg/L D-glucose, 2200 mg/L mM sodium bicarbonate; 15% ES qualified fetal calf serum (BRL); 2 mM glutamine (BRL); 1 mM sodium pyruvate (BRL); 1000-2000 U/mL human recombinant leukemia inhibitory factor (LIF, Genzyme); 1-2 ng/ml human recombinant basic fibroblast growth factor (bFGF, Genzyme); and 10 µM forskolin (in 10% DMSO). In an alternative approach, EG cells are 20 isolated using hyaluronidase/collagenase/DNAse. Gonadal anlagen or genital ridges with mesenteries are dissected from fetal material, the genital ridges are rinsed in PBS, then placed in 0.1 ml HCD digestion solution (0.01 % hyaluronidase type V, 0.002% DNase I, 0.1% collagenase type IV, all from Sigma prepared in EG growth medium). Tissue is minced and incubated 1 h or overnight at 37°C, resuspended in 1-3 mL of EG growth medium, and plated onto a feeder layer.

25 Ninety-six well tissue culture plates are prepared with a sub-confluent layer of feeder cells cultured for 3 days in modified EG growth medium free of LIF, bFGF or forskolin, inactivated with 5000 rad  $\gamma$ -irradiation. Suitable feeders are STO cells (ATCC Accession No. CRL 1503). ~0.2 mL of primary germ cell (PGC) suspension is added to each of the wells. The first passage is conducted after 7-10 days in EG growth 30 medium, transferring each well to one well of a 24-well culture dish previously prepared with irradiated STO mouse fibroblasts. The cells are cultured with daily replacement of medium until cell morphology consistent with EG cells are observed, typically after 7-30 days or 1-4 passages.

*Propagation of pPS Cells in an Undifferentiated State*

35 pPS cells can be propagated continuously in culture, using a combination of culture conditions that promote proliferation without promoting differentiation.

Traditionally, pPS cells are cultured on a layer of feeder cells, typically fibroblast type cells, often derived from embryonic or fetal tissue. The cell lines are plated to near confluence, usually irradiated to prevent proliferation, and then used to support pPS cell cultures.

40 In one illustration, pPS cells are first derived and supported on primary embryonic fibroblasts. Mouse embryonic fibroblasts (mEF) can be obtained from outbred CF1 mice (SASCO) or other suitable strains. The abdomen of a mouse at 13 days of pregnancy is swabbed with 70% ethanol, and the decidua is removed into phosphate buffered saline (PBS). Embryos are harvested; placenta, membranes, and soft tissues are removed; and the carcasses are washed twice in PBS. They are then transferred to fresh 10 cm bacterial dishes containing 2 mL trypsin/EDTA, and finely minced. After incubating 5 min at 37°C, the trypsin is

inactivated with 5 mL DMEM containing 10% bovine serum (FBS), and the mixture is transferred to a 15 mL conical tube and dissociated. Debris is allowed to settle for 2 min, the supernatant is made up to a final volume of 10 mL, and plated onto a 10 cm tissue culture plate or T75 flask. The flask is incubated undisturbed for 24 h, after which the medium is replaced. When flasks are confluent (~2-3 d), they are split 1:2 into new flasks.

5 Scientists at Geron have discovered that hPS cells can be maintained in an undifferentiated state even without feeder cells. The environment for feeder-free cultures includes a suitable culture substrate, particularly an extracellular matrix, such as may be derived from basement membrane or that may form part of adhesion molecule receptor-ligand couplings. A suitable preparation is available from Becton Dickenson under the name Matrigel®. Other extracellular matrix components and component mixtures are suitable as an alternative.

10 Depending on the cell type being proliferated, this may include laminin, fibronectin, proteoglycan, entactin, heparan sulfate, and the like, alone or in various combinations. Laminins are major components of all basal laminae in vertebrates, which interact with integrin heterodimers such as  $\alpha 6\beta 1$  and  $\alpha 6\beta 4$  (specific for laminins) and other heterodimers (that cross-react with other matrices).

15 The pluripotent stem cells are plated onto the substrate in a suitable distribution and in the presence of a medium that promotes cell survival, propagation, and retention of the desirable characteristics. It has been found that plating densities of at least  $\sim 15,000$  cells  $\text{cm}^2$  (typically  $90,000 \text{ cm}^2$  to  $170,000 \text{ cm}^2$ ) promote survival and limit differentiation. The passage of pPS cells in the absence of feeders benefits from preparing the pPS cells in small clusters. Typically, enzymatic digestion is halted before cells become completely dispersed (say,  $\sim 5$  min with collagenase IV). Clumps of  $\sim 10-2000$  cells are then plated directly onto the substrate without further dispersal. Alternatively, primate PS cells can be passaged between feeder-free cultures as a finer cell suspension, providing that an appropriate enzyme and medium are chosen, and the plating density is sufficiently high. By way of illustration, confluent human embryonic stem cells cultured in the absence of feeders are removed from the plates by incubating with a solution of 0.05% (wt/vol) trypsin (Gibco) and 0.053 mM EDTA for 5-15 min at 37°C. With the use of pipette, the remaining cells in the plate are removed

20 and the cells are triturated with the pipette until the cells are dispersed into a suspension comprising single cells and some small clusters. The cells are then plated at densities of 50,000-200,000 cells/ $\text{cm}^2$  to promote survival and limit differentiation. The phenotype of ES cells passaged by this technique is similar to what is observed when cells are harvested as clusters by collagen digestion. As another option, the cells can be harvested without enzymes before the plate reaches confluence. The cells are incubated  $\sim 5$  min in a solution of 0.5 mM

25 EDTA alone in PBS, washed from the culture vessel, and then plated into a new culture without further dispersal.

30 pPS cells plated in the absence of fresh feeder cells benefit from being cultured in a nutrient medium. The medium will generally contain the usual components to enhance cell survival, including isotonic buffer, essential minerals, and either serum or a serum replacement of some kind. Conditioned medium can be prepared by culturing irradiated primary mouse embryonic fibroblasts (or another suitable cell preparation) at a density of  $\sim 5-6 \times 10^4 \text{ cm}^2$  in a serum free medium such as KO DMEM supplemented with 20% serum replacement and 4 ng/mL basic fibroblast growth factor (bFGF). The culture supernatant is harvested after  $\sim 1$  day at 37°C.

35 As an alternative to primary mouse fibroblast cultures, conditioned medium can be prepared from an embryonic fibroblast cell line tested for its ability to condition medium appropriately. Such lines can optionally be transfected with telomerase reverse transcriptase to increase their replicative capacity. Another possible source is differentiated pPS cells with the morphological features of fibroblasts. pPS cells are suspension cultured as aggregates in differentiation medium using non-adherent cell culture plates ( $\sim 2 \times 10^6$  cells/ $9.6 \text{ cm}^2$ ). After 2 days the aggregates are transferred into gelatin-coated plates, and fibroblast-like cells appear in clusters

of 100-1000 cells in the mixed population after ~11 days. After brief collagenase treatment, the fibroblast-like cells can be collected under a microscope, passaged in mEF medium, and tested for their ability to condition ES medium.

Medium that has been conditioned for 1-2 days is typically used to support pPS cell culture for 1-2 days, and then exchanged. If desired, conditioned medium can be supplemented before use with additional growth factors that benefit pPS cell culture. For hES, a growth factor like bFGF or FGF-4 can be used. For hEG, culture medium may be supplemented with a growth factor like bFGF, an inducer of gp130, such as LIF or Oncostatin-M, and perhaps a factor that elevates cyclic AMP levels, such as forskolin.

10 *Characteristics of Undifferentiated pPS Cells*

In the two dimensions of a standard microscopic image, hES cells have high nuclear/cytoplasmic ratios in the plane of the image, prominent nucleoli, and compact colony formation with poorly discernable cell junctions. Cell lines can be karyotyped using a standard G-banding technique (available at many clinical diagnostics labs that provides routine karyotyping services, such as the Cytogenetics Lab at Oakland CA) and compared to published human karyotypes.

15 hES and hEG cells can also be characterized by expressed cell markers. In general, the tissue-specific markers discussed in this disclosure can be detected using a suitable immunological technique — such as flow cytometry for membrane-bound markers, immunohistochemistry for intracellular markers, and enzyme-linked immunoassay, for markers secreted into the medium. The expression of protein markers can also be detected at the mRNA level by reverse transcriptase-PCR using marker-specific primers. See U.S. Patent 5,843,780 for further details.

20 Stage-specific embryonic antigens (SSEA) are characteristic of certain embryonic cell types. Antibodies for SSEA markers are available from the Developmental Studies Hybridoma Bank (Bethesda MD). Other useful markers are detectable using antibodies designated Tra-1-60 and Tra-1-81 (Andrews et al., *Cell Lines from Human Germ Cell Tumors*, in E.J. Robertson, 1987, *supra*). hES cells are typically SSEA-1 negative and SSEA-4 positive. hEG cells are typically SSEA-1 positive. Differentiation of pPS cells in vitro results in the loss of SSEA-4, Tra-1-60, and Tra-1-81 expression and increased expression of SSEA-1. pPS cells can also be characterized by the presence of alkaline phosphatase activity, which can be detected by fixing the cells with 4% paraformaldehyde, and then developing with Vector Red as a substrate, as described 25 by the manufacturer (Vector Laboratories, Burlingame CA).

30 Embryonic stem cells are also typically telomerase positive and OCT-4 positive. Telomerase activity can be determined using TRAP activity assay (Kim et al., *Science* 266:2011, 1997), using a commercially available kit (TRAPezo® XK Telomerase Detection Kit, Cat. s7707; Intergen Co., Purchase NY; or TeloTAGGG™ Telomerase PCR ELISAPLus, Cat. 2,013,89; Roche Diagnostics, Indianapolis). hTERT expression can also be evaluated at the mRNA level by RT-PCR. The LightCycler TeloTAGGG™ hTERT 35 quantification kit (Cat. 3,012,344; Roche Diagnostics) is available commercially for research purposes.

Differentiating pPS Cells

40 Differentiation of the pPS can be initiated by first forming embryoid bodies. General principles in culturing embryoid bodies are reported in O'Shea, *Anat. Rec.* (New Anat. 257:323, 1999). pPS cells are cultured in a manner that permits aggregates to form, for which many options are available: for example, by overgrowth of a donor pPS cell culture, or by culturing pPS cells in culture vessels having a substrate with low adhesion properties which allows EB formation. Embryoid bodies can also be made in suspension culture.

pPS cells are harvested by brief collagenase digestion, dissociated into clusters, and plated in non-adherent cell culture plates. The aggregates are fed every few days, and then harvested after a suitable period, typically 4-8 days. The cells can then be cultured in a medium and/or on a substrate that promotes enrichment of cells of a particular lineage. The substrate can comprise matrix components such as Matrigel® (Becton Dickenson), 5 laminin, collagen, gelatin, or matrix produced by first culturing a matrix-producing cell line (such as a fibroblast or endothelial cell line), and then lysing and washing in such a way that the matrix remains attached to the surface of the vessel. Embryoid bodies comprise a heterogeneous cell population, potentially having an endoderm exterior, and a mesoderm and ectoderm interior.

Scientists at Geron Corporation have discovered that pPS cells can be differentiated into committed 10 precursor cells or terminally differentiated cells without forming embryoid bodies or aggregates as an intermediate step. Briefly, a suspension of undifferentiated pPS cells is prepared, and then plated onto a solid surface that promotes differentiation. Suitable substrates include glass or plastic surfaces that are adherent. For example, glass coverslips can be coated with a polycationic substance, such as a polyamines like poly-lysine, poly-ornithine, or other homogeneous or mixed polypeptides or other polymers with a predominant 15 positive charge. The cells are then cultured in a suitable nutrient medium that is adapted to promote differentiation towards the desired cell lineage.

In some circumstances, differentiation is further promoted by withdrawing serum or serum replacement from the culture medium. This can be achieved by substituting a medium devoid of serum and serum replacement, for example, at the time of replating. In certain embodiments of the invention, 20 differentiation is promoted by withdrawing one or more medium component(s) that promote(s) growth of undifferentiated cells, or act(s) as an inhibitor of differentiation. Examples of such components include certain growth factors, mitogens, leukocyte inhibitory factor (LIF), and basic fibroblast growth factor (bFGF). Differentiation may also be promoted by adding a medium component that promotes differentiation towards the desired cell lineage, or inhibits the growth of cells with undesired characteristics. For example, to generate 25 cells committed to neural or glial lineages, the medium can include any of the following factors or medium constituents in an effective combination: Brain derived neurotrophic factor (BDNF), neutrotrophin-3 (NT-3), NT-4, epidermal growth factor (EGF), ciliary neurotrophic factor (CNTF), nerve growth factor (NGF), retinol acid (RA), sonic hedgehog, FGF-8, ascorbic acid, forskolin, fetal bovine serum (FBS), and bone morphogenic proteins (BMPs).

30 General principals for obtaining tissue cells from pluripotent stem cells are reviewed in Pedersen (Reprod. Fertil. Dev. 6:543, 1994), and U.S. Patent 6,090,622. Other publications of interest include the following: For neural progenitors, neural restrictive cells and glial cell precursors, see Bain et al., Biochem. Biophys. Res. Commun. 200:1252, 1994; Trojanowski et al., Exp. Neurol. 144:92, 1997; Wojcik et al., Proc. Natl. Acad. Sci. USA 90:1305-130; and U.S. Patents 5,851,832, 5,928,947, 5,766,948, and 5,849,553. For 35 cardiac muscle and cardiomyocytes see Chen et al., Dev. Dynamics 197:217, 1993 and Wobus et al., Differentiation 48:173, 1991. For hematopoietic progenitors, see Burkert et al., New Biol. 3:698, 1991 and Biesecker et al., Exp. Hematol. 21:774, 1993. U.S. Patent 5,773,255 relates to glucose-responsive insulin secreting pancreatic beta cell lines. U.S. Patent 5,789,246 relates to hepatocyte precursor cells. Other progenitors of interest include but are not limited to chondrocytes, osteoblasts, retinal pigment epithelial cells, 40 fibroblasts, skin cells such as keratinocytes, dendritic cells, hair follicle cells, renal duct epithelial cells, smooth and skeletal muscle cells, testicular progenitors, and vascular endothelial cells.

Scientists at Geron Corporation have discovered that culturing pPS cells or embryoid body cells in the presence of ligands that bind growth factor receptors promotes enrichment for neural precursor cells. The growth environment may contain a neural cell supportive extracellular matrix, such as fibronectin. Suitable

growth factors include but are not limited to EGF, bFGF, PDGF, IGF-1, and antibodies to receptors for these ligands. The cultured cells may then be optionally separated by whether they express a marker such as A2B5. Under the appropriate circumstances, populations of cells enriched for expression of the A2B5 marker may have the capacity to generate both neuronal cells (including mature neurons), and glial cells (including 5 astrocytes and oligodendrocytes). Optionally, the cell populations are further differentiated, for example, by culturing in a medium containing an activator of cAMP.

Scientists at Geron Corporation have discovered that culturing pPS cells or embryoid body cells in the presence of a hepatocyte differentiation agent promotes enrichment for hepatocyte-like cells. The growth environment may contain a hepatocyte supportive extracellular matrix, such as collagen or Matrigel®. Suitable 10 differentiation agents include various isomers of butyrate and their analogs, exemplified by n-butyrate. The cultured cells are optionally cultured simultaneously or sequentially with a hepatocyte maturation factor, such as an organic solvent like dimethyl sulfoxide (DMSO); a maturation cofactor such as retinoic acid; or a cytokine or hormone such as a glucocorticoid, epidermal growth factor (EGF), insulin, TGF- $\alpha$ , TGF- $\beta$ , fibroblast growth factor (FGF), heparin, hepatocyte growth factor (HGF), IL-1, IL-6, IGF-I, IGF-II, and HBGF-1.

15 Scientists at Geron Corporation have discovered that it is also possible to differentiate hPS cells into a highly enriched population comprising cardiomyocytes or cardiomyocyte precursors. The cardiomyocyte lineage cells can be obtained, for example, by differentiating hES cells in a growth environment comprising a cardiotrophic factor that affects DNA-methylation, exemplified by 5-azacytidine. Spontaneously contracting cells can then be separated from other cells in the population, for example, by density centrifugation. Further 20 process steps can include culturing the cells in a medium containing creatine, carnitine, or taurine. Alternatively, it is possible to differentiate hPS cells into a highly enriched population comprising osteoprogenitors or osteoblasts expressing osteocalcin and collagen-1. The cells can be obtained by taking pPS-derived mesenchymal cells and differentiating them in a medium containing a bone morphogenic protein (particularly BMP-4), a ligand for a human TGF- $\beta$  receptor, or a ligand for a human vitamin D receptor.

25

#### *Characteristics of differentiated cells*

Cells can be characterized according to a number of phenotypic criteria. The criteria include but are not limited to characterization of morphological features, detection or quantitation of expressed cell markers and enzymatic activity, and determination of the functional properties of the cells *in vivo*.

30 Markers of interest for neural cells include  $\beta$ -tubulin III or neurofilament, characteristic of neurons; glial fibrillary acidic protein (GFAP), present in astrocytes; galactocerebroside (GalC) or myelin basic protein (MBP); characteristic of oligodendrocytes; OCT-4, characteristic of undifferentiated hES cells; nestin, characteristic of neural precursors and other cells. A2B5 and NCAM are characteristic of glial progenitors and neural progenitors, respectively. Cells can also be tested for secretion of characteristic biologically active substances. 35 For example, GABA-secreting neurons can be identified by production of glutamic acid decarboxylase or GABA. Dopaminergic neurons can be identified by production of dopa decarboxylase, dopamine, or tyrosine hydroxylase.

40 Markers of interest for liver cells include  $\alpha$ -fetoprotein (liver progenitors); albumin,  $\alpha_1$ -antitrypsin, glucose-6-phosphatase, cytochrome p450 activity, transferrin, asialoglycoprotein receptor, and glycogen storage (hepatocytes); CK7, CK19, and  $\gamma$ -glutamyl transferase (bile epithelium). It has been reported that hepatocyte differentiation requires the transcription factor HNF-4 $\alpha$  (Li et al., *Genes Dev.* 14:464, 2000). Markers independent of HNF-4 $\alpha$  expression include  $\alpha_1$ -antitrypsin,  $\alpha$ -fetoprotein, apoE, glucokinase, insulin growth factors 1 and 2, IGF-1 receptor, insulin receptor, and leptin. Markers dependent on HNF-4 $\alpha$  expression

include albumin, apoA1, apoAII, apoB, apoCIII, apoCII, aldolase B, phenylalanine hydroxylase, L-type fatty acid binding protein, transferrin, retinol binding protein, and erythropoietin (EPO).

Cell types in mixed cell populations derived from pPS cells can be recognized by characteristic morphology and the markers they express. For skeletal muscle: myoD, myogenin, and myf-5. For endothelial cells: PECAM (platelet endothelial cell adhesion molecule), Flk-1, tie-1, tie-2, vascular endothelial (VE) cadherin, MECA-32, and MEC-14.7. For smooth muscle cells: specific myosin heavy chain. For cardiomyocytes: GATA-4, Nkx2.5, cardiac troponin I,  $\alpha$ -myosin heavy chain, and ANF. For pancreatic cells, pdx and insulin secretion. For hematopoietic cells and their progenitors: GATA-1, CD34, AC133,  $\beta$ -major globulin, and  $\beta$ -major globulin like gene  $\beta$ H1.

10 Certain tissue-specific markers listed in this disclosure or known in the art can be detected by immunological techniques — such as flow immunocytochemistry for cell-surface markers, immunohistochemistry (for example, of fixed cells or tissue sections) for intracellular or cell-surface markers, Western blot analysis of cellular extracts, and enzyme-linked immunoassay, for cellular extracts or products secreted into the medium. The expression of tissue-specific gene products can also be detected at the mRNA level by Northern blot analysis, dot-blot hybridization analysis, or by reverse transcriptase initiated polymerase chain reaction (RT-PCR) using sequence-specific primers in standard amplification methods. Sequence data for the particular markers listed in this disclosure can be obtained from public databases such as GenBank (URL [www.ncbi.nlm.nih.gov:80/entrez](http://www.ncbi.nlm.nih.gov:80/entrez)).

20 **Preparing Cell Populations Essentially Free of Undifferentiated Cells**

In accordance with this Invention, populations of differentiated cells are depleted of relatively undifferentiated cells by expressing a gene that is lethal to cells or renders them susceptible to a lethal effect of an external agent, under control of a transcriptional control element that causes the gene to be preferentially expressed in the undifferentiated cells.

25 To accomplish this, the cells are genetically altered either before or after the process used to differentiate the cells into the desired lineage for therapy, in a way that puts an effector gene suitable for negative selection of undifferentiated cells, under control of a transcriptional control element with the desired properties.

30 ***Transcriptional Control Elements for Driving Negative Selection***

The control element is selected with a view to the protein expression patterns of the undifferentiated and differentiated cells in the population.

35 Genes with desirable expression patterns can be identified by comparing expression at the transcription, translation, or functional level in two different cell populations — one relatively enriched for differentiated cells, the other relatively enriched for undifferentiated cells. Suitable methods of comparison include subtractive hybridization of cDNA libraries, and microarray analysis of mRNA levels. Once a transcript is identified with an appropriate expression pattern, the promoter or enhancer of the corresponding gene can be used for construction of the negative selection vector.

40 A suitable microarray analysis is conducted using a Genetic Microsystems array generator, and an Axon GenePix™ Scanner. Microarrays are prepared by amplifying cDNA fragments in a 96 or 384 well format, and then spotted directly onto glass slides. To compare mRNA preparations from two cell populations, one preparation is converted into Cy3-labeled cDNA, while the other is converted into Cy5-labeled cDNA. The two cDNA preparations are hybridized simultaneously to the microarray slide, and then washed to eliminate non-

specific binding. Any given spot on the array will bind each of the cDNA products in proportion to abundance of the transcript in the two original mRNA preparations. The slide is then scanned at wavelengths appropriate for each of the labels, and the relative abundance of mRNA is determined. Preferably, the level of expression of the effector gene will be at least 5-fold or even 25-fold higher in the undifferentiated cells relative to the 5 differentiated cells.

For the depletion of pluripotent embryonic cells, an exemplary control element is the promoter for telomerase reverse transcriptase (TERT). Sequence of the human TERT gene (including upstream promoter sequence) is provided below. The reader is also referred to U.K. Patent GB 2321642 B (Cech et al., Geron Corporation and U. Colorado), International Patent Publications WO 00/46355 (Morin et al., Geron Corporation), WO 99/33998 (Hagen et al., Bayer Aktiengesellschaft), and Horikawa, I., et al. (Cancer Res., 59:826, 1999). Sequence of the mouse TERT gene is provided in WO 99/27113 (Morin et al., Geron Corporation). A lambda phage clone designated  $\lambda$ G $\Phi$ 5, containing ~13,500 bases upstream from the hTERT encoding sequence is available from the ATCC under Accession No. 98505. Example 9 illustrates the testing and use of TERT promoter sequences (SEQ. ID NO:1) in vector expression systems.

Another exemplary control element is a promoter sequence for Octamer binding transcription factor 4 (OCT-4), a member of the POU family of transcription factors. OCT-4 transcription is activated between the 4 and 80 cell stage in the developing embryo, and it is highly expressed in the expanding blastocyst and then in the pluripotent cells of the egg cylinder. Transcription is down-regulated as the primitive ectoderm differentiates to form mesoderm, and by 8.5 days post coitum is restricted to migrating primordial germ cells. High-level OCT-4 gene expression is also observed in pluripotent embryo carcinoma and embryonic stem cell lines, and is down-regulated when these cells are induced to differentiate. Pig, mouse, and human OCT-4 promoter sequences are provided in International Patent Publication WO 99/19469 (Biotransplant Inc.).

Other suitable control elements can be obtained from genes causing expression of markers characteristic of undifferentiated cells in the population but not of the differentiated cells. For example, SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81 are characteristic of various types of undifferentiated pluripotent embryonic stem cells. The enzyme responsible for synthesis of SSEA-4 may have transcriptional control elements with the desirable expression specificity. A more recent example is the promoter for *Rex1* protein, a retinoic acid regulated zinc finger protein that is expressed in preimplantation embryos. The mouse *Rex1* promoter has been shown to act as an effective transcription marker for undifferentiated embryonic stem cells (Eiges et al., Current Biol. 11:514, 2001).

Suitability of particular elements can be estimated by analysis of gene transcript expression, for example, by microarray analysis. Reporter constructs can then be tested in differentiated and undifferentiated cells for the appropriate specificity, using a promoter or enhancer sequence from the identified cell-specific gene to control transcription of a reporter gene, such as green fluorescence protein, secreted alkaline phosphatase,  $\beta$ -glucuronidase, or  $\beta$ -galactosidase. Use of reporter constructs to test promoter specificity is illustrated below in Example 9.

#### *Effector Genes for Achieving Negative Selection*

A transcriptional regulatory element with appropriate specificity is operatively linked to an encoding 40 region for a product that will provide elimination of cells in which it is expressed — either directly, or by rendering the cell susceptible to an otherwise innocuous external agent.

Suitable effector genes include those that encode a peptide toxin — such as ricin, abrin, diphtheria, gelonin, *Pseudomonas* exotoxin A, *Crotalus durissus terrificus* toxin, *Crotalus adamanteus* toxin, *Naja naja* toxin, and *Naja mocambique* toxin. Hughes et al., Hum. Exp. Toxicol. 15:443, 1996; Rosenblum et al., Cancer

Immunol. Immunother. 42:115, 1996; Rodriguez et al., Prostate 34:259, 1998; Mauceri et al., Cancer Res. 56:4311; 1996.

Also suitable are genes that induce or mediate apoptosis — such as the ICE-family of cysteine proteases, the Bcl-2 family of proteins, Bax, bclXs and caspases (Favrot et al., Gene Ther. 5:728, 1998; McGill et al., Front. Biosci. 2:D353, 1997; McDonnell et al., Semin. Cancer Biol. 6:53, 1995). Another potential anti-tumor agent is apotin, a protein that induces apoptosis even where small drug chemotherapeutics fail (Pietersen et al., *Adv. Exp. Med. Biol.* 465:153, 2000). Koga et al. (Hu. Gene Ther. 11:1397, 2000) propose a telomerase-specific gene therapy using the hTERT gene promoter linked to the apoptosis gene Caspase-8 (FLICE). Gu et al. (Cancer Res. 60:5359, 2000) reported a binary adenoviral system that induced Bax expression via the hTERT promoter. They found that it elicited tumor-specific apoptosis in vitro and suppressed tumor growth in nude mice.

Also of interest are enzymes present in the lytic package that cytotoxic T lymphocytes or LAK cells deliver to their targets. Perforin, a pore-forming protein, and Fas ligand are major cytolytic molecules in these cells (Brandau et al., Clin. Cancer Res. 6:3729, 2000; Cruz et al., Br. J. Cancer 81:881, 1999). CTLs also express a family of at least 11 serine proteases termed granzymes, which have four primary substrate specificities (Kam et al., *Biochim. Biophys. Acta* 1477:307, 2000). Low concentrations of streptolysin O and pneumolysin facilitate granzyme B-dependent apoptosis (Browne et al., *Mol. Cell Biol.* 19:8604, 1999).

Other suitable effectors encode polypeptides having activity that is not itself toxic to a cell, but renders the cell sensitive to an otherwise nontoxic compound — either by metabolically altering the cell, or by changing a non-toxic prodrug into a lethal drug. Lethality to progeny with an undifferentiated phenotype only occurs when the prodrug is present. Thus, the prodrug can be combined with the cells while they are being differentiated, expanded, or maintained in vitro, to minimize the proportion of cells with undifferentiated phenotype. The reader will readily appreciate that the prodrug can also be given to a patient being treated with the cells, either simultaneously with the treatment, or at a subsequent time, in order to minimize the emergence of progeny with an undifferentiated phenotype in vivo.

Exemplary effector genes with this property encode thymidine kinase (*tk*), such as may be derived from a herpes simplex virus, and catalytically equivalent variants. The HSV *tk* converts the anti-herpetic agent ganciclovir (GCV) to a toxic product that interferes with DNA replication in proliferating cells.

U.S. Patent 5,631,236 (Baylor College of Medicine) outlines adenoviral vectors containing an HSV *tk* gene operatively linked to a promoter that expresses *tk* in cancer cells. U.S. Patent 5,997,859 and EP 702084 B1 (Chiron) pertain to replication-defective recombinant retrovirus, carrying a vector construct directing expression of HSV *tk* gene for converting an otherwise inert compound into a cytotoxic form. EP 415731 A1, EP 657540 A1, and EP 657541 A1 (Wellcome Foundation) propose retroviral vectors encoding an enzyme such as VZV *tk*, carboxypeptidase G2, alkaline phosphatase, penicillin-V amidase, and cytosine deaminase, for converting a prodrug into an agent toxic to a cancer cell. International Patent Publications WO 98/14593 and WO 00/46355 (Geron Corporation) describe constructs comprising HSV *tk* under control of hTERT promoter sequences.

The human HSV *tk* gene sequence is provided below (SEQ. ID NOS:2 & 3), along with illustrations of its use to target cells expressing TERT. Simultaneously or following expression of the gene in target cells, a convertible prodrug such as ganciclovir is added to the environment to effect depletion of the targets.

Another type of effector that renders the cell susceptible to an otherwise non-toxic agent is a gene that causes presentation of a foreign antigen on the cell membrane. The presented substance may be an alloantigen, a xenoantigen, or an antigen from a non-mammalian species for which specific antibody is readily available. Expression of the gene leads to presentation of the antigen on undifferentiated cells, which then can

be used to effect depletion by a suitable immunological separation — such as immunoaffinity (e.g., panning), fluorescence-activated cell sorting, or complement-mediated lysis.

When the transducing agent is a viral vector, the effector can be a viral gene required for replication of the virus. Essential genes for replication of adenovirus include the E4, E1a, E1b, and E2 regions. Essential genes for replication of HSV-1 include ICP6 and ICP4. These genes are placed under control of the specific promoter, and used to transduce cells in the differentiated cell population. The viruses then replicate specifically in any undifferentiated cells present, causing them to rupture. See International Patent Publication WO 00/46355 (Morin et al., Geron Corporation) for a description of lytic vectors that replicate in cells expressing TERT.

Another type of effector sequence encodes a membrane protein that contains the epitope recognized by the specific antibody. The membrane protein may be a protein expressed in the same species or other types of cells, but more typically is obtained from another species, or is an artificial sequence. In this case, the antigen will be foreign to the species from which the stem cells are derived, and antibodies made in the same species will not cross-react with other antigens on the cell.

Alternatively, the target antigen can be a cell-surface carbohydrate or lipid component. In this case, the effector sequence will encode an enzyme involved in antigen synthesis. Of particular interest are glycosyl transferases of mammalian or non-mammalian origin that synthesize carbohydrate differentiation antigen, alloantigen, xenoantigen, or novel determinants detectable by antibody. Examples include the marker SSEA-1, for which the effector sequence encodes the corresponding fucosyltransferase; the Gal $\alpha$ (1,3)Gal linkage present on endothelial tissue of most mammals except for humans and old-world monkeys, formed by an  $\alpha$ (1,3)galactosyltransferase ( $\alpha$ 1,3GT); and the ABO histo blood group antigens present on most human cells, for which the encoding sequence is the corresponding ABO transferase. See GenBank Accession Nos. S71333, J05175, and AF134414. The Gal $\alpha$ (1,3)Gal and ABO determinants are all susceptible to lysis mediated by antibodies that naturally occur in subjects that do not have the determinants as a self-antigen.

Another possible effector sequence is based on RNA-interference (RNAi) technology. Double-stranded or hairpin RNA corresponding to a portion of mature mRNA in a cell (such as a gene transcript) cause the target mRNA to be destroyed (Sharp et al., *Genes Dev.* 13:139, 1999; Wianny et al., *Nat. Cell Biol.* 2:70, 2000). For example, a plasmid containing a promoter that drives expression of a hairpin RNA (a transcript consisting of inverted repeats taken from the coding region of a cellular gene, separated by a short linker sequence, thus generating a synthetic RNA containing a double-stranded region) has been used to induce stable and inheritable RNAi effects in *C. elegans* (Tavernarakis et al.; *Nat. Genet.* 24:180, 2000).

In certain embodiments of this invention, a control element driving transcription in an undifferentiated cell (or a cell expressing TERT) is operatively linked to an encoding sequence for hairpin RNAi that targets a particular gene transcript. The target gene is chosen to be essential for cell viability: for example, a basic transcription or translation factor, a tRNA gene, a ribosomal RNA subunit, or DNA or RNA polymerase. In one illustration, the hTERT promoter drives RNAi that inactivates a gene in the purine salvage pathway. In the presence of drugs such as aminopterin, *de novo* synthesis of purines is prevented, because the activity of the enzymes hypoxanthine-guanine phosphoribosyl transferase (HGPRT) and thymidine kinase (TK) is inhibited. Cells that possess HGPRT and TK survive in the presence of aminopterin, as long as the medium is supplemented with hypoxanthine and thymidine (HAT medium). Residual undifferentiated cells can be removed from the population by incubation with HAT medium. Transcripts of essential genes such as HGPRT and TK can also be targeted using other types of effector sequences — for example, antisense

polynucleotides, ribozymes, or encoding sequences for dominant negative analogs that lack a functional catalytic domain.

The effector region used in the vectors of this invention can be constructed so as to be functionally controlled by a molecular switch. Fusions between the ligand-binding domain of receptors result in molecules

5 in which the normal function of the native protein is inhibited in the absence of the hormone recognized by the ligand-binding domain. A fusion protein is constructed comprising a switch molecule binding domain coupled to an effector domain, in such a way that binding of a ligand (such as a small molecule hapten) to the binding domain unmasks or activates the effector domain. Suitable ligand binding domains can be taken from a receptor (such the estrogen receptor) or an antibody. The effector domain can be any of the proteins already listed that are lethal to the cell, such as peptide toxins, endonucleases (meganucleases such as I-Sce -1 or humanized versions of standard restriction endonucleases), or mediators of apoptosis. The lethal function of the effector gene is quiescent, unless the ligand is present. This provides another system where the effector gene renders the cell susceptible to toxic effects of an external agent (in this case the ligand), which can be administered at will to control the depletion of undifferentiated cells, either in culture or in vivo.

10 15 The vector constructs for use in this invention can also contain a positive selection marker, such as an antibiotic resistance gene, that is also under control of the specific promoter. Exemplary is a vector having the configuration hTERT promoter - tk gene - IRES - neo. This is designed so that both the suicide effector and drug resistance gene are expressed under control of the TERT promoter. The internal ribosome entry site (IRES) sequence allows both the tk gene and the neo gene to be under transcriptional control of the hTERT promoter. A post-translational cleavage site, such as 2A sequences (Felipe et al., Gene Ther. 6:198, 1999) can be used to similar effect. Generation and selection of hES lines that have stably integrated such a construct is facilitated by the activity of the drug resistance gene in the undifferentiated cells. This has an advantage over co-transfection methods using a drug resistant gene under control of a different promoter, because the drug resistance gene will not be expressed in differentiated cells. This should avoid an unwanted immunological response by the host against the gene product in transplanted cells.

#### *Selection Techniques to Eliminate Undifferentiated Cells*

To deplete differentiated cell populations of undifferentiated cells, the effector gene is selectively expressed in the undifferentiated cells.

20 30 This can be accomplished in several ways. In one embodiment, the population is genetically altered using a vector in which a transcriptional control element of the appropriate specificity is operatively linked to the effector gene. The genetic alteration may be transient (for example, using an adenovirus vector), meaning that the level of expression diminishes as the cells divide. This is suitable for generating differentiated cell populations that will be free of heterologous genes at the time of therapy. The genetic alteration may also be 35 permanent (for example, using a retroviral vector), meaning that the alteration is inheritable by progeny of the initially altered cell. This is suitable for generating differentiated cell populations that will have an ongoing corrective function as they proliferate in vitro or in vivo, to eliminate any undifferentiated or dedifferentiated cells that arise in the population.

40 Any suitable expression vector can be used. Suitable viral vector systems for producing stem cells altered according to this invention can be prepared using commercially available virus components. Viral vectors comprising effector genes are generally described in the publications referenced in the last section. Alternatively, vector plasmids can be introduced into cells by electroporation, or using lipid/DNA complexes, such as those described in U.S. Patent Nos. 5,578,475; 5,627,175; 5,705,308; 5,744,335; 5,976,567; 6,020,202; and 6,051,429. Exemplary is the formulation Lipofectamine 2000™, available from Gibco/Life

Technologies. Another exemplary reagent is FuGENE™ 6 Transfection Reagent, a blend of lipids in non-liposomal form and other compounds in 80% ethanol, obtainable from Roche Diagnostics Corporation.

In another embodiment, the effector gene is placed under control of an endogenous transcriptional control element, such as the hTERT or OCT-4 promoter. This can be effected, for example, by homologous recombination, using a vector comprising the effector encoding sequence, flanked on one side by the transcriptional control element and other upstream genomic sequence, and flanked on the other side by downstream genomic sequence for the targeted gene. U.S. Patent Nos. 5,464,764 and 5,631,153 describe a double-selection strategy, in which two sequences homologous to the gene target flank a positive selection marker, and a negative selection marker is attached to the 3' terminal of the second flanking region. U.S. Patent 5,789,215 reports the use of homologous recombination targeting vectors for modifying the cell genome of mouse embryonic stem cells. Other information of interest for homologous recombination targeting can be found in U.S. Patents 5,589,369, 5,776,774, and 5,789,215.

If the effector gene directly causes cell lysis or apoptosis, then the population will be depleted of undifferentiated cells upon culturing the cells under conditions where the control element is expected to cause transcription of the gene. However, if the effector gene is not directly lethal, but renders the cell susceptible to the lethal effects of an external agent, then depletion will be postponed until the external agent is provided. For example, where the gene is a prodrug converting enzyme, then depletion is effected upon placing the cells in an environment containing the prodrug. Where the gene is an antibody target, then depletion is effected upon placing the cells in an environment containing specific antibody, plus complement. The environment can be a culture vessel, in which case the agent can just be added to the culture medium at the requisite concentration. Alternatively or in addition, depletion can be performed *in vivo*, by administering the cell population to a subject, and simultaneously or sequentially administering the agent, if not already present.

Cell populations in which the majority of cells are differentiated can be genetically modified according to these procedures to deplete undifferentiated cells. Alternatively, a precursor population of relatively undifferentiated cells can be genetically modified according to these procedures, and then differentiated. In this situation, it is more typical to use an effector gene that does not kill the cells immediately upon expression, but renders the cells susceptible to the lethal effect of some external agent. In one illustration, undifferentiated pPS cells grown in culture are transduced with a retrovirus vector in which the herpes thymidine kinase gene is under control of the hTERT promoter. The cells are optionally selected for positive transduction, either by incorporating a selectable marker in the construct, or by measuring expression of the transduced gene, and proliferated in culture. When differentiated cells are desired, the population is taken through a differentiation procedure (for example, to make hepatocyte or neuron precursors, as described earlier). They are then cultured under conditions that permit expression of the *tk* gene in the presence of ganciclovir.

As an illustration where RNAi is the effector sequence, hES cells are stably transfected (e.g., by lipofection) with a construct consisting of 2 cassettes: one in which the PGK promoter drives the neomycin phosphotransferase gene (resulting in resistance to toxic neomycin analogs such as geneticin); the other in which the hTERT promoter drives an encoding region for RNAi that contains double-stranded regions from HGPRT or TK. Stably modified clones are isolated in a medium containing both geneticin and azaguanine or 6-mercaptopurine (to select for HGPRT negative cells), or in medium containing both geneticin and 5-bromodeoxyuridine (to select for TK negative cells). Alternatively, the transfection could be done with just the RNAi kit, in which case geneticin is omitted from the medium. After isolation of the surviving clones, these lines are induced to differentiate to the desired cell type, and exposed to HAT medium to kill any residual stem cells.

Cell populations may be obtained using these techniques that are "depleted" of undifferentiated cells, which indicates any significant reduction in the proportion of undifferentiated cells present. After the procedure

is effected, the proportion of undifferentiated cells may be decreased by 50% or even 90%. Depending on the control element and effector chosen, it may be possible to achieve differentiated cell populations that are "essentially free" of undifferentiated cells. This means that the population as a whole contains less than 1% of cells with the undifferentiated phenotype. Populations containing less than 0.2%, 0.05%, 0.01%, 20 ppm or 5 ppm undifferentiated cells are increasingly more preferred. For pPS cells, the presence of undifferentiated cells can be determined by counting cells expressing SSEA-4 by FACS analysis, or by counting cells expressing TERT or OCT-4 by fluorescence in-situ hybridization.

#### Use of Differentiated Cells

10 Cells prepared according to this invention can be used for a variety of commercially important research, diagnostic, and therapeutic purposes.

Because the cell populations of this invention are depleted of undifferentiated cells, they can be used to prepare antibodies and cDNA libraries that are specific for the differentiated phenotype. General techniques used in raising, purifying and modifying antibodies, and their use in immunoassays and immunosolation 15 methods are described in *Handbook of Experimental Immunology* (Weir & Blackwell, eds.); *Current Protocols in Immunology* (Coligan et al., eds.); and *Methods of Immunological Analysis* (Masseyeff et al., eds., Weinheim: VCH Verlags GmbH). General techniques involved in preparation of mRNA and cDNA libraries are described in *RNA Methodologies: A Laboratory Guide for Isolation and Characterization* (R.E. Farrell, Academic Press, 1998); *cDNA Library Protocols* (Cowell & Austin, eds., Humana Press); and *Functional Genomics* (Hunt & 20 Livesey, eds., 2000).

Relatively homogeneous cell populations are particularly suited for use in drug screening and therapeutic applications.

#### *Drug Screening*

25 Differentiated pPS cells of this invention can be used to screen for factors (such as solvents, small molecule drugs, peptides, polynucleotides, and the like) or environmental conditions (such as culture conditions or manipulation) that affect the characteristics of differentiated cells.

In some applications, differentiated cells are used to screen factors that promote maturation, or 30 promote proliferation and maintenance of such cells in long-term culture. For example, candidate maturation factors or growth factors are tested by adding them to pPS cells in different wells, and then determining any phenotypic change that results, according to desirable criteria for further culture and use of the cells.

Particular screening applications of this invention relate to the testing of pharmaceutical compounds in drug research. The reader is referred generally to the standard textbook "In vitro Methods in Pharmaceutical Research", Academic Press, 1997, and U.S. Patent 5,030,015). Assessment of the activity of candidate 35 pharmaceutical compounds generally involves combining the differentiated cells of this invention with the candidate compound, determining any change in the morphology, marker phenotype, or metabolic activity of the cells that is attributable to the compound (compared with untreated cells or cells treated with an inert compound), and then correlating the effect of the compound with the observed change.

The screening may be done, for example, either because the compound is designed to have a 40 pharmacological effect on certain cell types, or because a compound designed to have effects elsewhere may have unintended side effects. Two or more drugs can be tested in combination (by combining with the cells either simultaneously or sequentially), to detect possible drug-drug interaction effects. In some applications, compounds are screened initially for potential toxicity (Castell et al., pp. 375-410 in "In vitro Methods in

Pharmaceutical Research," Academic Press, 1997). Cytotoxicity can be determined in the first instance by the effect on cell viability, survival, morphology, and expression or release of certain markers, receptors or enzymes. Effects of a drug on chromosomal DNA can be determined by measuring DNA synthesis or repair. [<sup>3</sup>H]thymidine or BrdU incorporation, especially at unscheduled times in the cell cycle, or above the level required for cell replication, is consistent with a drug effect. Unwanted effects can also include unusual rates of sister chromatid exchange, determined by metaphase spread. The reader is referred to A. Vickers (PP 375-410 in "In vitro Methods in Pharmaceutical Research," Academic Press, 1997) for further elaboration.

5 ***Therapeutic Use***  
10 Differentiated cells of this invention can also be used for tissue reconstitution or regeneration in a human patient in need thereof. The cells are administered in a manner that permits them to graft to the intended tissue site and reconstitute or regenerate the functionally deficient area.

15 In one example, neural stem cells are transplanted directly into parenchymal or intrathecal sites of the central nervous system, according to the disease being treated. Grafts are done using single cell suspension or small aggregates at a density of 25,000-500,000 cells per  $\mu$ L (U.S. Patent 5,968,829). The efficacy of neural cell transplants can be assessed in a rat model for acutely injured spinal cord as described by McDonald et al. (Nat. Med. 5:1410, 1999. A successful transplant will show transplant-derived cells present in the lesion 2-5 weeks later, differentiated into astrocytes, oligodendrocytes, and/or neurons, and migrating along the cord from the lesioned end, and an improvement in gate, coordination, and weight-bearing.

20 Certain neural progenitor cells embodied in this invention are designed for treatment of acute or chronic damage to the nervous system. For example, excitotoxicity has been implicated in a variety of conditions including epilepsy, stroke, ischemia, Huntington's disease, Parkinson's disease and Alzheimer's disease. Certain differentiated cells of this invention may also be appropriate for treating dysmyelinating disorders, such as Pelizaeus-Merzbacher disease, multiple sclerosis, leukodystrophies, neuritis and 25 neuropathies. Appropriate for these purposes are cell cultures enriched in oligodendrocytes or oligodendrocyte precursors to promote remyelination.

25 Hepatocytes and hepatocyte precursors prepared according to this invention can be assessed in animal models for ability to repair liver damage. One such example is damage caused by intraperitoneal injection of D-galactosamine (Dabeva et al., Am. J. Pathol. 143:1606, 1993). Efficacy of treatment can be 30 determined by immunohistochemical staining for liver cell markers, microscopic determination of whether canalicular structures form in growing tissue, and the ability of the treatment to restore synthesis of liver-specific proteins. Liver cells can be used in therapy by direct administration, or as part of a bioassist device that provides temporary liver function while the subject's liver tissue regenerates itself following fulminant hepatic failure.

35 The efficacy of cardiomyocytes prepared according to this invention can be assessed in animal models for cardiac cryoinjury, which causes 55% of the left ventricular wall tissue to become scar tissue without treatment (Li et al., Ann. Thorac. Surg. 62:654, 1996; Sakai et al., Ann. Thorac. Surg. 8:2074, 1999, Sakai et al., J. Thorac. Cardiovasc. Surg. 118:715, 1999). Successful treatment will reduce the area of the scar, limit scar expansion, and improve heart function as determined by systolic, diastolic, and developed pressure.

40 Cardiac injury can also be modeled using an embolization coil in the distal portion of the left anterior descending artery (Watanabe et al., Cell Transplant. 7:239, 1998), and efficacy of treatment can be evaluated by histology and cardiac function. Cardiomyocyte preparations embodied in this invention can be used in therapy to regenerate cardiac muscle and treat insufficient cardiac function (U.S. Patent 5,919,449 and WO 99/03973).

*The examples that follow are provided by way of further illustration, and are not meant to imply any limitation in practicing the claimed invention.*

5

EXAMPLESExample 1; Feeder-free passage of hES cells

In this experiment, undifferentiated hES cells that had been maintained on primary mouse embryonic feeder cells were harvested, and then maintained in the absence of feeders. The culture wells were coated 10 with Matrigel®, and the cells were cultured in the presence of conditioned nutrient medium obtained from a culture of irradiated primary fibroblasts.

*Preparation of conditioned media (CM) from primary mouse embryonic fibroblasts (mEF):*

Fibroblasts were harvested from T150 flasks by washing one time with Ca<sup>++</sup>/Mg<sup>++</sup> free PBS and 15 incubating in 1.5-2 mL trypsin/EDTA (Gibco) for about 5 min. After the fibroblasts detached from the flask, they were collected in mEF media (DMEM + 10% FBS). The cells were irradiated at 4000 rad (508 sec at 140kV: shelf setting 6 in a Torrex™ generator), counted and seeded at about 55,000 cells cm<sup>-2</sup> in mEF media (525,000 cells/well of a 6 well plate). After at least 4 hours the media were exchanged with SR containing ES media 20 (containing bFGF), using 3-4 mL per 9.6 cm well of a 6 well plate. Conditioned media was collected daily for feeding of hES cultures. Alternatively, medium was prepared using mEF plated in culture flasks, exchanging medium daily at 0.3-0.4 mL cm<sup>-2</sup>. Before addition to the hES cultures, the conditioned medium was supplemented with 4 ng/mL of human bFGF (Gibco). Fibroblasts cultures were used in this system for about 1 week, before replacing with newly prepared cells.

25 *Matrigel® coating:*

Growth Factor Reduced Matrigel® or regular Matrigel® (Becton-Dickinson, Bedford MA) was thawed at 4°C. The Matrigel® was diluted 1:10 to 1:500 (typically 1:30) in cold KO DMEM. 0.75-1.0 mL of solution was added to each 9.6 cm<sup>2</sup> well, and incubated at room temp for 1 h. The coated wells were washed once with cold KO DMEM before adding cells. Plates were used within 2 h after coating, or stored in DMEM at 4°C and used 30 within ~1 week.

*Human ES culture:*

Undifferentiated hES colonies were harvested from hES cultures on feeders as follows. Cultures were incubated in ~200 U/mL collagenase IV for about 5 minutes at 37 °C. Colonies were harvested by picking 35 individual colonies up with a 20 µL pipet tip under a microscope or by scraping and dissociating into small clusters in conditioned medium (CM). These cells were then seeded onto Matrigel® in conditioned media at 15 colonies to each 9.6 cm<sup>2</sup> well (if 1 colony is ~10,000 cells, then the plating density is ~15,000 cells cm<sup>-2</sup>).

The day after seeding on Matrigel®, hES cells were visible as small colonies (~100-2,000 cells) and there were single cells in-between the colonies that appeared to be differentiating or dying. As the hES cells 40 proliferated, the colonies became quite large and very compact, representing the majority of surface area of the culture dish. The hES cells in the colonies had a high nucleus to cytoplasm ratio and had prominent nucleoli, similar to hES cells maintained on feeder cells. At confluence, the differentiated cells in between the colonies represented less than 10% of the cells in the culture.

Six days after seeding, the cultures had become almost confluent. The cultures were split by incubating with 1 mL ~200 U/mL Collagenase IV solution in KO DMEM for ~5 minutes at 37 °C. The collagenase solution was aspirated, 2 mL hES medium was added per well, and the hES cells were scraped from the dish with a pipette. The cell suspension was transferred to a 15 mL conical tube, brought up to a 5 volume of 6 mL, and gently triturated to dissociate the cells into small clusters of 10-2000 cells. The cells were then re-seeded on Matrigel® coated plates in CM, as above. Cells were seeded at a 1:3 or 1:6 ratio, approximately 90,000 to 170,000 cells cm<sup>-2</sup>, making up the volume in each well to 3 mL. Medium was changed daily, and the cells were split and passaged again at 13 d and again at 19 d after initial seeding.

On day 19 after initial seeding, cells were harvested and evaluated for surface marker expression by 10 immunofluorescence cell cytometry, using labeled antibodies specific for cell surface markers. For the hES cells maintained in the absence of feeders, a high percentage express SSEA-4, Tra-1-60 or Tra-1-81. These 3 markers are expressed on undifferentiated human ES cells that are maintained on feeders (Thomson et al., 1998). In addition, there is very little expression of SSEA-1, a glycolipid that is not expressed (or expressed at 15 low levels) on undifferentiated ES cells. Immunohistochemical evaluation of SSEA-4, Tra-1-60 and Tra-1-81 indicates that the expression of these markers is localized to the ES colonies, not the differentiated cells in between the colonies.

Cultures of hES cells have been grown in the absence of feeder cells for over 180 days after initial seeding, with no apparent change in the proliferative capacity or phenotype. Human ES cells maintained on Matrigel® in mEF conditioned medium have a doubling time of about 31-33 hours, similar to the proliferation 20 rate for hES cells grown on mEF feeder cells. H1 cells after 64 days of feeder-free culture showed a normal karyotype.

Example 2: Phenotypic markers of hES cells in feeder-free culture

Undifferentiated hES cells express SSEA-4, Tra-1-60, Tra-1-81, OCT-4, and hTERT. The expression 25 of these markers decreases upon differentiation. In order to assess whether the cells maintained in feeder-free conditions retained these markers, cells were evaluated by immunostaining, reverse transcriptase PCR amplification, and assay for telomerase activity.

For analysis by fluorescence-activated cell sorting (FACS), the hES cells were dissociated in 0.5 mM EDTA in PBS and resuspended to about  $5 \times 10^5$  cells in 50 µL diluent containing 0.1% BSA in PBS. For 30 analyzing surface marker expression, cells were incubated in the primary antibodies, including IgG isotype control (0.5 µg/test), IgM isotype control (1:10), SSEA-1 (1:10), SSEA-4 (1:20), Tra-1-60 (1:40) and Tra-1-81 (1:80), diluted in the diluent at 4°C for 30 min. After washing with the diluent, cells were incubated with rat anti-mouse kappa chain antibodies conjugated with PE (Becton Dickinson, San Jose, CA) at 4°C for 30 min. Cells were washed and analyzed on FACScalibur™ Flow Cytometer (Becton Dickinson, San Jose, CA) using 35 CellQuest™ software.

Similar to the hES cells on feeders, cells on Matrigel®, laminin, fibronectin or collagen IV expressed SSEA-4, Tra-1-60 and Tra-1-81. There was very little expression of SSEA-1, a glycolipid that is not expressed by undifferentiated hES cells.

For analysis by immunocytochemistry, cells were incubated with primary antibodies, including SSEA-1 (1:10), SSEA-4 (1:20), Tra-1-60 (1:40) and Tra-1-81 (1:80), diluted in knockout DMEM at 37°C for 30 min. Cells were then washed with warm knockout DMEM and fixed in 2% paraformaldehyde for 15 min. After 40 washing with PBS, cells were incubated with 5% goat serum in PBS at room temp for 30 min, followed by incubation with the FITC-conjugated goat anti-mouse antibodies (1: 125) (Sigma) at room temp for 30 min.

Cells were washed, stained with DAPI and mounted. The staining was typically performed ~2 days after passaging. Cells were also examined for expression of alkaline phosphatase, a marker for undifferentiated ES cells. This was performed by culturing the cells on chamber slides, fixing with 4 % paraformaldehyde for 15 min, and then washing with PBS. Cells were then incubated with alkaline phosphatase substrate (Vector 5 Laboratories, Inc., Burlingame, CA) at room temperature in the dark for 1 h. Slides were rinsed for 2-5 min in 100% ethanol before mounting.

The results showed that SSEA-4, Tra-1-60, Tra-1-81, and alkaline phosphatase were expressed by the hES colonies on Matrigel® or laminin, as seen for the cells on feeders — but not by the differentiated cells in between the colonies.

10 Figure 1 shows OCT-4 and hTERT expression of H1 cells on feeders and off feeders, as detected by reverse-transcriptase PCR amplification. For radioactive relative quantification of individual gene products, QuantumRNA™ Alternate18S Internal Standard primers (Ambion, Austin TX, USA) were employed according to the manufacturer's instructions. Briefly, the linear range of amplification of a particular primer pair was determined, then coamplified with the appropriate mixture of alternate18S primers:competimers to yield PCR 15 products with coinciding linear ranges. Before addition of AmpliTaq™ (Roche) to PCR reactions, the enzyme was pre-incubated with the TaqStart™ antibody (ProMega) according to manufacturer's instructions. Radioactive PCR reactions were analyzed on 5% non-denaturing polyacrylamide gels, dried, and exposed to phosphoimage screens (Molecular Dynamics) for 1 hour. Screens were scanned with a Molecular Dynamics Storm 860 and band intensities were quantified using ImageQuant™ software. Results are expressed as the 20 ratio of radioactivity incorporated into the hTERT or OCT-4 band, standardized to the radioactivity incorporated into the 18s band.

Primers and amplification conditions for particular markers are as follows. OCT-4: Sense (SEQ. ID NO:4) 5'-CTTGCTGCAG AAGTGGGTGG AGGAA-3'AntiSense (SEQ. ID NO:5) 5'-CTGCAGTGTG GGTTTCGGGC A-3'; alternate18:competimers 1:4; 19 cycles (94° 30 sec; 60° 30 sec; 72° 30 sec). hTERT: 25 Sense (SEQ. ID NO:6) 5'-CGGAAGAGTG TCTGGAGCAA-3'AntiSense (SEQ. ID NO:7) 5'-GGATGAAGCG GAGTCTGGA-3'; alternate18:competimers 1:12; 34 cycles (94° 30 sec; 60° 30 sec; 72° 30 sec).

hTERT and OCT-4 expression was seen in all the culture conditions except Matrigel® and regular medium. Furthermore, after exposure of cells to retinoic acid (RA) or dimethyl sulfoxide (DMSO), factors that promote cell differentiation, the expression of hTERT was markedly decreased.

30 Figure 2 shows telomerase activity measured by TRAP activity assay (Kim et al., Science 266:2011, 1997; Weinrich et al., Nature Genetics 17:498, 1997). All the cultures conditions showed positive telomerase activity after 40 days on Matrigel®, laminin, fibronectin or collagen IV in mEF conditioned medium.

#### Example 3: Differentiation of hES cells

35 In this experiment, differentiation using standard methods of aggregate formation was compared with a direct differentiation technique.

For the aggregate differentiation technique, monolayer cultures of rhesus and human ES lines were harvested by incubating in Collagenase IV for 5-20 min, and the cells were scraped from the plate. The cells were then dissociated and plated in non-adherent cell culture plates in FBS-containing medium. The plates 40 were placed into a 37°C incubator, and in some instances, a rocker was used to facilitate maintaining aggregates in suspension. After 4-8 days in suspension, aggregate bodies formed and were plated onto a substrate to allow for further differentiation.

For the direct differentiation technique, suspensions of rhesus and human ES cells were prepared in a similar fashion. The cells were then dissociated by trituration to clusters of ~50-100 cells, and plated onto glass coverslips treated with poly-ornithine. The cells were maintained in serum containing medium, or defined medium for 7-10 days before analysis.

5 Cells from both preparations were fixed and tested by immunoreactivity for  $\beta$ -tubulin III and MAP-2, which is characteristic of neurons, and glial fibrillary acidic protein (GFAP), which is characteristic of astrocytes. Results are shown in Table 1.

TABLE 1: Comparison of hPS Differentiation Methods

ES Cell Line used for differentiation	Differentiation via Aggregate Bodies		Direct Differentiation	
	Neurons	Astrocytes	Neurons	Astrocytes
R366.4 (Rhesus line)	+	+	+	+
R278.5 (Rhesus line)	+	+	+	+
R456 (Rhesus line)	+	+	+	+
H9 (Human line)	+	+	+	+
H9.1 (Clone of H9)	(Not Done)	(Not Done)	+	+
H9.2 (Clone of H9)	+	+	+	+

10 Rhesus and human ES lines differentiated into cells bearing markers for neurons and astrocytes, using either the aggregate or direct differentiation technique. In the rhesus cultures, percentage of aggregates that contained neurons ranged from 49% to 93%. In the human lines examined, the percentage of aggregates containing neurons ranged from 60% to 80%. Double labeling for GABA and  $\beta$ -tubulin indicated that a subpopulation of the neurons express the inhibitory neurotransmitter GABA. In addition, astrocytes and oligodendrocytes were identified with GFAP immune reactivity and GalC immune reactivity, respectively. Therefore, the human and rhesus ES cells have the capacity to form all three major cell phenotypes in the central nervous system.

15 The effect of several members of the neurotrophin growth factor family was examined. hES cells were differentiated by harvesting with collagenase, dissociating, and reseeding onto poly-ornithine coated cover slips. The cells were plated into DMEM/F12 + N2 + 10% FBS overnight. The following day, the serum was removed from the medium and replaced with 10 ng/mL human bFGF and the growth factor being tested. After 24 hours, bFGF was removed from the medium. These cultures were fed every other day. They were fixed after 7 days of differentiation and immunostained for analysis. The number of neurons was evaluated by counting cells positive for  $\beta$ -tubulin. Cultures maintained in the presence of 10 ng/mL brain derived neurotrophic factor (BDNF) formed approximately 3-fold more neurons than the control cultures. Cultures maintained in neurotrophin-3 (1 ng/mL) formed approximately 2-fold more neurons than control cultures.

20 In a subsequent experiment, suspensions of human ES cells were prepared from parental line H9 and two subcloned lines. The cells were harvested using collagenase IV, and then replated onto poly-ornithine coated glass slides in medium containing 20% FBS. The cultures were then fed every other day for 7-10 days, 25 then fixed for immunostaining. From each of these lines, a number of differentiated cells stained positively for

muscle-specific actin (antibody from Dako), but were negative for cardiac troponin I. Several patches of cells stained positively for  $\alpha$ -fetoprotein, indicating the presence of endoderm cells.

Example 4: Comparison of direct differentiation with differentiation through embryoid bodies

5 To induce direct differentiation, undifferentiated hES cells were harvested and re-plated directly into differentiating conditions. Considerable cell death was apparent upon plating, but many cells adhered and began to proliferate and/or differentiate. In cultures differentiated using serum containing conditions, the cultures continued to proliferate and reached confluence within 5-10 days. At this time, the cultures contained a heterogeneous population that displayed many different morphologies. Immunocytochemistry revealed  
10 ectoderm, mesoderm and endoderm lineages using antibodies against  $\beta$ -tubulin III, muscle specific actin and  $\alpha$ -fetoprotein, respectively. The positive staining for all of these cell types appeared in patches that were sometimes quite dense, therefore it was difficult to accurately quantify the percentages of each cell type.

15 In order to increase the percentage of neurons, the hES cells were plated onto poly-ornithine coated glass coverslips and cultures in defined media. Although these data indicate that cells from all three germ layers can be derived without the production of EBs, cardiomyocytes were not identified.

20 By way of comparison, hES cells were induced to differentiate by generating embryoid bodies (EBs). In these experiments, ES cells were harvested and replated in suspension cultures. Although initially a marked amount of cell death was observed, after 2-3 days the remaining cells formed aggregates. EBs were maintained for as many as 16 days in culture and were still viable and formed many structures after subsequent plating. Later stage human EBs often showed a cystic morphology and sometimes gave rise to beating EBs.

25 To assess cardiomyocyte formation, EBs were transferred to gelatin-coated plates or chamber slides after 4 days in the suspension cultures. The EBs attached to the surface after seeding, proliferated and differentiated into different types of cells. Spontaneously contracting cells were observed in various regions of the culture at differentiation day 8 and the number of beating regions increased until about day 10. In some cases, more than 75% of the EBs had contracting regions. Beating cells were morphologically similar to mouse ES cell-derived beating cardiomyocytes. In addition, the expression of the cardiac specific marker cardiac troponin I was examined at differentiation day 15 using immunocytochemistry. Individual contracting foci in the differentiated cultures were photographed to record the contracting area before the culture was fixed. The culture was then evaluated for cardiac cTnI expression and matched to the original photographs to determine  
30 the percentage of contracting areas that were positive for cTnI staining. As a control, cells adjacent to the contracting foci were also examined for cTnI staining. In these cultures 100% of the contracting areas showed positive immunoreactivity, while minimal immunoreactivity was observed in the non-beating cells.

35 Cultures of differentiated EBs were subjected to Western blot analysis using monoclonal antibody against cTnI. This assay gave a strong 31 kDa protein signal, corresponding to the size of the purified native human cardiac Tn I. cTnI was detected in differentiated human ES cells containing contracting cells but not in undifferentiated ES cells or differentiated cultures with no evidence of contracting cells, suggesting the specific detection of cardiomyocytes. As a control, the blot was reprobed with  $\beta$ -actin specific antibody, confirming the presence of similar amounts of proteins in all samples.

40 In other experiments, EBs were cultured for 8 or 16 days and maintained as adherent cultures for an additional 10 days. RNA was prepared from the differentiated human ES cells and semiquantitative RT-PCR was performed to detect the relative expression of the endoderm-specific products  $\alpha_1$ -anti-trypsin, AFP, and albumin. Low levels of  $\alpha_1$ -anti-trypsin and AFP were detected in the undifferentiated cultures; little or no albumin was detected in the same cultures. All 3 markers were detected at significantly higher levels after

differentiation. Expression of all 3 endoderm markers was higher in cultures derived from 8 day embryoid bodies than 16 day embryoid bodies.

Example 5: Transfection and transduction of hES cells maintained on primary mEF feeder layers

5 hES cultures were maintained in a growth medium composed of 80% KO DMEM (Gibco) and 20% Serum Replacement (Gibco) supplemented with 1% non-essential amino acids, 1 mM glutamine, 0.1 mM B-mercaptoethanol and 4 ng/mL hbFGF (Gibco).  
Plates were coated with a solution of 0.5% gelatin (Sigma) at 37° overnight before the addition of cells. Primary mEFs were cultured in standard mEF medium, and split 1:2 every 2 days for up to 5 splits. Subconfluent 10 cultures of mEFs were detached with trypsin, resuspended in 10 mL medium, and irradiated with a cumulative dose of 3500-4000 rads with a Torrex™ 150D X-ray generator. Irradiated cells were pelleted at 400 x g for 5 min and resuspended at  $1.25 \times 10^5$  cells per mL in standard mEF medium. Individual wells of a 6-well plate were seeded with  $3.75 \times 10^5$  irradiated mEFs per well; individual wells of a 24-well plate were seeded with 75,000 irradiated mEFs per well.  
15 Transfection was performed as follows. hES cells plated in 6 well plates were removed from the feeder layer with collagenase (~200 units/mL) at 37° for 7-10 min. When colonies began to detach, the collagenase from each well was aspirated and replaced with 2 mL of standard hES growth medium/well. The hES cells were removed by scraping the surface of a single well with a 5 mL pipet and transferred to a 50 mL conical tube. Additional hES growth medium was added to a final volume of 10 mL. The cell suspension was 20 triturated 10-12 times with a 10 mL pipet, and an additional 8 mL of standard hES growth medium added. Three mL of the cell suspension were added to each well of 6 well plates that were pre-coated with gelatin and mEF feeder layers as described above (i.e., 1 well of a 6 well plate was sufficient to seed 6 wells of a new plate).

25 Replated hES cells were tested with a number of different transfection systems to determine whether genetic alteration of hES cells could be achieved without causing differentiation. Systems tested included the following: Mammalian Transfection Kit (CaPO4 and DEAE reagents), Stratagene cat # 200285; TransIT-LT1 Mirus™ (Panvera), cat # MIR 2310; Polybrene (Sigma); Poly-L-Lysine (Sigma); Superfect™ (Qiagen); Effectene™ (Qiagen); Lipofectin™ (Life Technologies); Lipofectamine (differs from Lipofectamine 2000™) (Life Technologies); Cellfectin™ (Life Technologies); DMRIE-C (Life Technologies); Lipofectamine 2000 (Life 30 Technologies); and electroporation using BioRad™ Gene pulser.

35 Under the conditions used, Lipofectamine 2000™ (Gibco Life Technologies cat # 11668019, patent pending) and FuGENE™ (trademark of Fugent L.L.C.; a proprietary blend of lipids and other components, purchased from Roche Diagnostic Corporation cat # 1 814 443) both resulted in good transfection efficiency. The efficiency was generally best if these reagents were contacted with replated hES cells ~48 h after the replating.

Transfection using Lipofectamine 2000™ was conducted as follows: The plasmid DNA (3-5 µg of pEGFP-C1, ClonTech cat. # 6084-1) was diluted in water to a final volume of 100 µL. In pilot experiments, 5 to 40  $\mu$ L of Lipofectamine 2000™ (Gibco, cat # 11668-019) were diluted in OptiMEM™ (Gibco, cat # 11-58-021) to a final volume of 100 µL. The DNA solution was then added slowly to the Lipofectamine2000™ solution and mixed gently. The mixture was incubated at room temperature for 20-30 min before being supplemented with 800 µL of OptiMEM™. Cells were washed with 3 mL of pre-warmed OptiMEM™ and incubated in 0.5-1 mL of the DNA/lipid mixture solution at 37°C for 4 h, per well ( $9.6 \text{ cm}^2$ ). In some experiments, at 4 h the complex was removed before the addition of 4 mL of mEF-conditioned medium; in others sufficient mEF-conditioned medium

was added to the wells to reach a final volume of 3.5 mL and the mixture was left on the cells overnight. In other experiments the DNA/lipid mixture was added to wells containing sufficient mEF-conditioned medium such that the final volume was 3.5 mL, and the cells were incubated in this mixture overnight.

Transfection using FuGENE™ was conducted as follows. Each well was transfected with 10  $\mu$ g DNA 5 using FuGENE™ 6 (Roche Diagnostics Corp.), at a ratio of 3:2 FuGENE™ reagent to DNA as described by the manufacturer's directions. OptiMEM™ serum-free medium was used in the transfections. In the "old protocol", 4 h after the addition of the FuGENE™-DNA complex, 2.5 mL of standard hES growth medium was added to each transfected well. In the revised protocol ("3:2 L"), transfected wells were not re-fed with standard hES growth medium. Twenty-four hours after transfection, GFP-expression was assessed by flow cytometry.

10 Forty-eight hours before transfection, hES cells were seeded onto 6 well plates that had been coated with gelatin and mEF feeder layers as described above. hES cells were transfected using FuGENE™ 6 (Roche) or Lipofectamine 2000™ (Gibco) according to the manufacturers' instructions. Twenty-four hours after transfection, cells were assessed for GFP expression by inspection under a fluorescent microscope or flow cytometry. In the experiment shown in Fig. 1, three methods were compared: the standard Lipofectamine 15 2000™ protocol, the standard FuGENE™ protocol, and a variant FuGENE™ protocol in which the DNA/lipid mix was left on the cells overnight. The results demonstrated that while Lipofectamine 2000™ consistently yielded a higher percentage of GFP-expressing cells, the variant FuGENE™ protocol resulted in GFP-expressing cells with a higher mean fluorescence intensity.

Transient transductions using adenoviral vectors were conducted as follows. The vector 20 Ad5CMV5-GFP (referred to here as Ad5GFP) contains the green fluorescent protein encoding region under control of the CMV promoter, and was purchased from Quantum Biotechnologies, cat # ADV0030. Seventy-two hours before transduction, hES cells were seeded onto 24 well plates that had been coated with gelatin and mEF feeder layers as described above. Before transduction, 3 wells of hES cells were detached with a solution of 0.05% trypsin/5mM EDTA (Sigma) at 37°, resuspended in 500  $\mu$ L of standard mEF growth medium, 25 and counted with a hemocytometer (the 75,000 mEF feeder cells were subtracted from each well) to establish the cell number before transfection. The adenovirus stock was thawed on ice immediately prior to use.

For infection with Ad5GFP, growth media was aspirated from the wells containing hES cells and replaced with 1 mL of hES growth medium plus 9  $\mu$ L of Ad5 GFP stock (MOI of 40). Two hours later, the virus-containing medium was replaced with 1 mL of hES growth medium per well. Each transduced well was re-fed 30 with 1 mL of fresh hES growth medium every 24 hours. GFP expression was assessed by flow cytometry. The results from a typical experiment indicated that expression was highest at 24 hr after transduction but persisted for at least 8 days at low levels (by the later time points, extensive differentiation had occurred due to overgrowth of the hES cells).

35 Example 6: Preparation of the immortalized feeder cell line NH190

In this example, a permanent mouse cell line was established that is suitable for conditioning medium for the culture of primate pluripotent stem (pPS) cells. The NHG190 line is a mouse embryonic fibroblast cell line immortalized with telomerase that is triple drug resistant, and expresses green fluorescent protein (GFP).

Two mouse strains were obtained from Jackson Laboratory (Bar Harbor, Maine) that have a transgene 40 for resistance to the antibiotics neomycin or hygromycin. The C57BL/6J TgN(pPGKneobpA)3Ems mice and C57BL/6J-TgN(pPWL512hyg)1Ems mice from Jackson Labs were cross-bred. Embryos that were both neomycin- and hygromycin-resistant were dissected at day 13.5 post conception according to standard protocols for preparing mouse embryonic fibroblasts (mEF) for feeder layers (E.J. Robertson, pp. 71-112 in

*Teratocarcinoma and Embryonic Stem Cell Lines*, ed. E. J. Robertson, Oxford: IRL Press, 1987). The derived mEF cells were stored frozen.

5 The mEFs were thawed in growth medium containing 20% fetal calf serum (HyClone), 2 mM L-glutamine (Gibco/BRL), 80% DMEM (Gibco/BRL). The cells were expanded using 1:2 split ratios for 4 passages. Two flasks that had reached ~75% confluence were fed with fresh medium 4 h before electroporation. Cells were removed from the flasks with 0.5% trypsin/500 mM EDTA (Gibco/BRL), pelleted at 400  $\times$  g for 5 min at room temperature, and resuspended in the growth medium at a concentration of  $4 \times 10^6$  cells/mL.

10 The cell suspension was divided into two 500  $\mu$ L aliquots and transferred to two 0.4 cm gap electroporation cuvettes (BioRad). One cuvette received 5  $\mu$ g of the control plasmid (pBS212; puromycin-resistance gene driven by the SV40 early enhancer/promoter); the other received 5  $\mu$ g of pGRN190, comprising the murine telomerase reverse transcriptase (mTERT) coding region driven by MPSV promoter plus puromycin resistance gene driven by the SV40 early enhancer/promoter. The cells and DNA were mixed by hand, and electroporated using a BioRad gene Pulser with a BioRad capacitance extender at a setting of 300V, 960  $\mu$ F.

15 Each aliquot of cells was transferred to an individual 150 cm<sup>2</sup> plate containing 25 mL of growth medium. The medium on the plates was exchanged on the following day, and on the next day, growth medium was replaced by growth medium plus 0.5  $\mu$ g/mL puromycin. The medium on the plates was exchanged for fresh puromycin-containing medium every 48 hrs until 29 days after electroporation. At this time, large individual colonies of puromycin-resistant cells were evident in both the pBS212- and pGRN190- electroporated 20 plates. Ten colonies from the control plate and 12 from the pGRN190-electroporated plate were isolated with cloning cylinders and each colony was transferred to 1 well of a 48-well plate (1 well per colony).

25 One week later, all surviving colonies that had expanded to reach confluence in the 48 well plate (three control colonies, 1 pGRN190-electroporated colony) were transferred individually to wells of a 24 well plate. Six days later, the only colony that had continued to expand was derived from the pGRN190-electroporated plate, and was subsequently designated NH190. The cells were maintained in growth medium plus 0.5  $\mu$ g/mL puromycin. Analysis for telomerase activity by TRAP assay (Kim et al., *Nucleic Acids Res.* 25:2595, 1997) demonstrated that NH190 cells express functional telomerase activity.

30 To facilitate monitoring of the cells in mixed culture populations and in vivo, NH190 cells were further infected with a retroviral construct conferring expression of green fluorescent protein (GFP). The enhanced GFP sequence from plasmid pEGFP-1 is one of the Living Colors™ fluorescent protein vectors, available from ClonTech. It contains an enhanced GFP encoding region, with changes that alter restriction nuclease cleavage sites, and shift the excitation and emission wavelengths of the encoded protein. The EGFP-1 sequence was cloned into the vector pMSCV.neo, ClonTech cat # K1062-1. NH190 cells were transduced with the engineered vector, and GFP positive cells were separated by FACS sorting. The GFP expressing cell line was 35 designated NHG190. These cells have been carried in culture for over 3 months.

Example 7: Genetic modification of hES cells maintained on NHG190 feeder cells

40 NHG190 cells were cultured in DMEM (Gibco) plus 20% fetal bovine serum (HyClone) and 5 mM glutamine. Cells were split 1:10 every 3 d. Subconfluent cultures were detached with trypsin, suspended in 10 mL medium, and irradiated with a cumulative dose of 3500 rads with a Torrex™ 150D X-ray generator. Irradiated cells were pelleted at 400  $\times$  g for 5 min and resuspended at  $1.25 \times 10^5$  cells per mL in either NHG190 medium or standard hES medium.

Conditioned medium was prepared by plating NHG190 cells at  $4.08 \times 10^4 \text{ cm}^{-2}$  on gelatin-coated plates. At 18-24 h after plating, medium was exchanged for standard hES medium with 4 ng/mL added bFGF. The medium was conditioned by the cells for 18-24 h, harvested, and an additional 4 ng/mL bFGF was added. The medium was used to support hES cell cultures the same day as it was collected. Irradiated NHG190 cells 5 could be used for preparing conditioned medium for 7-10 days.

hES cells were transfected as follows. The cells were removed from the feeder layer using collagenase (~200 U/mL) at 37°C for 7-10 min, and transferred to a 50 mL conical tube. hES growth medium was added to a final volume of 10 mL; the suspension was triturated 10-12 times with a 10 mL pipet, and another 8 mL hES medium was added. Three mL of cell suspension was added to each well in a 6-well plate 10 precoated with Matrigel® and NHG190 feeder cells.

Forty-eight hours after seeding, the hES were transfected with 10  $\mu\text{g}$  DNA per well using FuGENE™ 6 (Roche) according to manufacturer's protocol in OptiMEM™ serum-free medium. The DNA was a plasmid 15 containing the PGK promoter driving neo'. Four h later, 3 mL of NHG190-conditioned medium was added to each transfected well. Cells were re-fed daily with 3 mL conditioned medium. Forty-eight h after transfection, the cells were layered with NHG190 conditioned medium containing 200  $\mu\text{g}/\text{mL}$  added geneticin (Sigma), which was replaced daily thereafter. After 3 days of selection, additional irradiated NHG190 feeder cells were added 15 (1.25  $\times 10^5$  cells/well in hES medium). Twenty-four h later, the medium was again replaced with NHG190-conditioned medium containing 200  $\mu\text{g}/\text{mL}$  geneticin, replaced daily.

Individual colonies were isolated and expanded through another round of selection. After a further 5 20 days, individual colonies were identified by microscope and marked on the outside of the dish. Medium was removed, and replaced with collagenase (~200 U/mL). Individual colonies were picked using a p20 pipet tip, and transferred to individual tubes containing 2 mL NHG190 conditioned medium (without geneticin). The suspension was triturated 5 times to disaggregate colonies, and the contents of each tube were transferred to a well of a 12-well plate coated with gelatin and irradiated NHG190 cells (1.875  $\times 10^5$  cells/well). Cells were fed 25 24 h later with 2 mL fresh conditioned medium. Two days after seeding, cells were layered with 2 mL conditioned medium containing 200  $\mu\text{g}/\text{mL}$  geneticin, replaced daily for 5 days. As each well became 50-75% confluent, the cells were detached with collagenase, transferred to 6 mL conditioned medium, and triturated 10-12 times. 3 mL cell suspension was added to each of 2 wells of a 6-well plated coated with gelatin and irradiated NHG190 cells (3.75  $\times 10^5$  cells/well); the cells were refed with 3 mL conditioned medium at 24 h. The 30 cells were then selected for 5 days using 3 mL conditioned medium containing geneticin, and split 1:6 as before.

Stable transduction using retrovirus was conducted as follows. Retroviral vector designated GRN354 was constructed at Geron Corp. using PMSCVneo vector purchased from ClonTech (cat # K1062-1). The 35 eGFP encoding region was inserted downstream from the MSCV LTR. The LTR drives expression of GFP and the vector also contains the *neo'* gene driven by the murine PGK promoter. Plates were coated with 0.5% gelatin and NHG190 feeder cells ( $7.5 \times 10^4$  in 1 mL NHG190 medium for 24 well plates;  $3.75 \times 10^5$  in 3 mL medium for 6 well plates). The hES line H7 was seeded onto a 24 well prepared plate in hES medium (1 mL/well). Forty-eight h later, 3 wells of hES cells were detached using 0.05% trypsin/5 mM EDTA (Sigma) at 37°C, resuspended in 500  $\mu\text{L}$  NHG190 medium, and counted. Stock of retrovirus construct pGRN354 was 40 thawed on ice immediately prior to use. Growth medium was aspirated from the wells and replaced with 400  $\mu\text{L}$  hES medium plus 8  $\mu\text{L}$  retrovirus (MOI of 10) and 4  $\mu\text{L}$  of 8 mg/mL polybrene solution (Sigma). Two h later, 800  $\mu\text{L}$  hES growth medium were added per well. Each transduced well was refed with 1 mL fresh hES medium every 24 h.

Four days after transduction, medium was replaced with 1 mL hES growth medium containing 200  $\mu$ g/mL geneticin. After 3 days of geneticin selection, the cells were detached with collagenase, triturated, resuspended in 3 mL hES medium, reseeded into one well of a 6-well plate coated with gelatin and NHG190 feeders, and refed with hES medium after 24 h. The medium was then again replaced with hES medium containing geneticin and refed every 24 h. Undifferentiated colonies survived the selection, and have been maintained for over 3 months. FACS analysis showed that 50-65% of the selected cells express GFP, albeit at low levels. The karyotype of the cells was normal.

Figure 3 shows GFP expression of hES cells transduced with retrovirus and then differentiated. The hES cell line H7 was plated on drug resistant (NHG190) feeder layers, infected with GRN354 and selected for resistance to the drug G418. Transduced cells were expanded and maintained under G418 selection for multiple passages. The cells were transferred to suspension culture to form embryoid bodies, allowed to differentiate for 4 days, and then plated in 20% FBS medium for 1 week. After extensive differentiation occurred, cultures were fixed in 4% paraformaldehyde and photographed under fluorescence for GFP expression. Many of the differentiated cells express higher levels of GFP than the undifferentiated transfected hES line, consistent with differential activation of the MESV-LTR in different cell types.

Example 8: Transfection of feeder-free hES cells

In this example, hES cells maintained in feeder-free culture on laminin in conditioned medium were genetically modified by transfecting with a plasmid carrying green fluorescent protein (GFP) driven by the CMV promoter.

mEF conditioned medium was prepared as described earlier. mEFs were irradiated and seeded at about  $5.7 \times 10^4$  cells/cm<sup>2</sup>. After at least 16 hours the medium was exchanged with hES medium including 4 ng/mL added hbFGF. Conditioned medium was collected daily for feeding of hES cultures. Before addition to the hES cultures, this medium was supplemented with an additional 4 ng/mL of hbFGF. Where needed for selection of stable transfecants, the mEF-conditioned medium was supplemented with 200  $\mu$ g/mL geneticin (Sigma cat. # G5013).

H9 hES cells maintained on mEF feeder layers were harvested from cultures by incubation with ~200 units/mL collagenase IV at 37°C for 10 min. Cells were dissociated and resuspended in regular hES culture medium or mEF-conditioned medium. Cells in the regular medium were then re-seeded onto mEF feeder layers and cells in the mEF-conditioned medium were plated onto Matrigel® or laminin. Seeding density for all cultures was approximately  $4 \times 10^4$  cells/cm<sup>2</sup>. Cells on feeder layers were maintained in regular medium while cells on matrices were maintained in mEF- conditioned medium for 1 or 2 days before the transfection. Conditioned medium was replaced every 24 h.

hES cell cultures were transfected with Lipofectamine 2000™ as described above. FACS analysis of GFP expression was conducted as follows. hES cells were harvested using 0.5mM EDTA in PBS and resuspended at approximately  $1 \times 10^6$  cells/test. Cells were washed in a solution containing PBS plus 2% FBS, 0.1% sodium azide, and 2 mM EDTA. SSEA-4 staining was performed in the same buffer using antibody obtained from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City) at 1:15 dilution. Isotype matched controls were obtained from Sigma, (St. Louis MO, USA). Cells were incubated with antibodies in a final volume of 100  $\mu$ l for 30 min at 4°C, washed and incubated with rat anti-mouse  $\kappa$  chain antibodies conjugated with PE (Becton Dickinson, San Jose, CA) at 4°C for 30 min. Samples were washed as before and analyzed for GFP and SSEA-4 expression on FACScalibur™ flow cytometer (Becton Dickinson, San Jose, CA) using CellQuest™ software.

hES cells of the H9 line maintained on laminin in mEF-conditioned medium were transfected with a plasmid carrying GFP driven by the CMV promoter at 24 or 48 h after plating. Initial experiments used a mixture of 5  $\mu$ g of plasmid and 12  $\mu$ L of Lipofectamine 2000<sup>TM</sup>. Cells received 1 mL of DNA/lipid complex and were incubated for 4 h at 37° before the addition of 3 mL of mEF-conditioned medium, and then monitored for 5 GFP expression 24 h after transfection.

Figure 4 shows the results of this experiment. Panel A: morphology of H9 cells maintained on laminin. Panel B: GFP-positive cells observed in the same colony shown in A. Panel C: FACS analysis of % GFP-positive cells in SSEA-4 high population(undifferentiated cells). Cells were transfected 24 (bar 1 and 2) or 10 48 h (bar 3 and 4) after the seeding and analyzed 24 (bar 1 and 3) or 48 h (bar 2 and 4) after the transfection. Bright green cells were observed in compact areas of undifferentiated ES colonies on laminin 24 h after transfection (Panels A & B). Transfection at 48 h after initial seeding gave the highest efficiency: 38% of the 15 cells were GFP-positive as determined by FACS analysis 24 h after the transfection (Panel C).

The next experiment compared the transfection efficiency of H9 cells maintained on Matrigel® or laminin-coated plates in mEF-conditioned medium with cells maintained on mEF feeders. Cells on feeder 15 layers maintained in regular medium were used as a control. Morphological differences between cells on feeders and cells off feeders were observed 1 or 2 days after seeding. Colonies on feeders were more compact than cells maintained off feeder layers; individual hES cells in feeder-free cultures were less compact and flatter. There was no significant difference in cell or colony morphology between cells on laminin and cells on Matrigel. These cells were transfected with a plasmid expressing GFP driven by the CMV promoter 2 days 20 after seeding. Twenty-four hours after the transfection, cells were examined for GFP expression under a fluorescence microscope.

The cells were maintained on mEF feeders in regular medium (mEF/RM), on laminin in medium conditioned by mEF (Laminin/CM) or on Matrigel® in the conditioned medium (Matrigel/CM). Bright green cells were observed in undifferentiated hES colonies of feeder-free cultures. In contrast, very few green cells were 25 found in colonies on feeders. FACS analysis showed that 16% of cells on Matrigel® and 14% of cells on laminin were GFP positive in SSEA-4 high population while only 5% of cells on feeders were positive. These results indicate that transfection efficiency is significantly increased by using feeder-free conditions.

The next experiments evaluated the effects of 1) the ratio of DNA:lipid; 2) adding the DNA/lipid complex to cells 4 h prior to the addition of mEF-conditioned medium vs. addition of the complex to cells in the 30 presence of mEF-conditioned medium; and 3) use of Lipofectamine 2000<sup>TM</sup> vs. FuGENE<sup>TM</sup>.

Transfection using Lipofectamine2000<sup>TM</sup> is described above. Transfection with FuGENE<sup>TM</sup> was conducted as follows. The plasmid DNA (5-10  $\mu$ g of pEGFP-C1, ClonTech cat. # 6084-1) was diluted in water 35 to a final volume of 100  $\mu$ L. In pilot experiments, 5-30  $\mu$ L of FuGENE<sup>TM</sup> were added to sufficient OptiMEM<sup>TM</sup> to achieve a final volume of 100  $\mu$ L. The DNA solution was then added slowly to the FuGENE<sup>TM</sup> solution and mixed gently. The mixture was incubated at room temperature for 30 min before being supplemented with 800  $\mu$ L of OptiMEM<sup>TM</sup>. Cells were washed with 3 mL of pre-warmed OptiMEM<sup>TM</sup> and incubated in 1 mL of the DNA/lipid mixture solution at 37° for 4 h. In some experiments, at 4 h the wells received an additional 2 mL of mEF-conditioned medium; in others the DNA/lipid mixture was added to wells containing 2 mL of mEF-conditioned medium and the cells were incubated in this mixture overnight.

40 Highest efficiencies were obtained under the following conditions: Bar 1 = a mixture of 5  $\mu$ g plasmid plus 12  $\mu$ L of Lipofectamine 2000<sup>TM</sup>, adding 1 mL of the DNA/lipid mixture to wells containing 2.5 mL of mEF-conditioned medium and incubating the cells in this mixture overnight. Bars 2 & 3 = a mixture of 10  $\mu$ g plasmid plus 15  $\mu$ L of FuGENE<sup>TM</sup> and incubating the cells in 1 mL of the DNA/lipid mixture for 4 h before adding 2.5 mL of mEF-conditioned medium. L=Lipofectamine2000<sup>TM</sup>; F=FuGENE<sup>TM</sup>.

To investigate whether the feeder-free hES cells undergo stable genetic modification, H1 hES cells maintained on Matrigel® were cotransfected with a mixture of 7.5 µg plasmid carrying β-galactosidase driven by the EF1a promoter, and 2.5 µg of plasmid carrying the PGK promoter driving the neophosphotransferase gene. The cells were transfected 48 h after plating them on Matrigel® in mEF-conditioned medium. 10 µg of plasmid plus 15 µl of FuGENE™ were incubated with the cells in 1 mL for 4 h before adding 2.5 mL of mEF-conditioned medium. After 48 h, medium was exchanged for mEF-conditioned medium supplemented with 200 µg/mL geneticin. Cultures were maintained in this geneticin-containing medium with daily medium exchange for over 21 days. All mock-transfected cultures (i.e., those that received FuGENE™ mixed with water rather than plasmid) died within 48-72 h. Drug resistant colonies arose in the wells transfected with both FuGENE™ and plasmid at a frequency of about 1 in to 10<sup>5</sup> originally transfected cells. The colonies were maintained in geneticin-containing mEF-conditioned medium and expanded.

Example 9: Preparation of vectors in which a thymidine kinase gene is under control of an hTERT promoter sequence

15 The lambda clone designated λGΦ5 containing the hTERT promoter is deposited with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VI 20110 U.S.A., under Accession No. 98505. λGΦ5 contains a 15.3 kbp insert including approximately 13,500 bases upstream from the hTERT coding sequence.

20 A Not1 fragment containing the hTERT promoter sequences was subcloned into the Not1 site of pUC derived plasmid, which was designated pGRN142. A subclone (plasmid "pGRN140") containing a 9 kb Ncol fragment (with hTERT gene sequence and about 4 to 5 kb of lambda vector sequence) was partially sequenced to determine the orientation of the insert. pGRN140 was digested using Sall to remove lambda vector sequences, the resulting plasmid (with removed lambda sequences) designated pGRN144. The pGRN144 insert was then sequenced.

25 SEQ. ID NO:1 is a listing of the sequence data obtained. Nucleotides 1-43 and 15376-15418 are plasmid sequence. Thus, the genomic insert begins at residue 44 and ends at residue 15375. The beginning of the cloned cDNA fragment corresponds to residue 13490. There are Alu sequence elements located ~1700 base pairs upstream. The sequence of the hTERT insert of pGRN142 can now be obtained from GenBank (<http://www.ncbi.nlm.nih.gov/>) under Accession PGRN142.INS AF121948. Numbering of hTERT residues for 30 plasmids in the following description begins from the translation initiation codon, according to standard practice in the field. The hTERT ATG codon (the translation initiation site) begins at residue 13545 of SEQ. ID NO:1. Thus, position -1, the first upstream residue, corresponds to nucleotide 13544 in SEQ. ID NO:1.

35 Expression studies were conducted with reporter constructs comprising various hTERT upstream and intron sequences. A BgIII-Eco47III fragment from pGRN144 (described above) was digested and cloned into the BgIII-Nrul site of pSEAP2Basic (ClonTech, San Diego, CA) to produce plasmid designated pGRN148. A second reporter-promoter, plasmid pGRN150 was made by inserting the BgIII-FspI fragment from pGRN144 into the BgIII-Nrul sites of pSEAP2. Plasmid pGRN173 was constructed by using the EcoRV-StuI (from +445 to -2482) fragment from pGRN144. This makes a promoter reporter plasmid that contains the promoter region of hTERT from approximately 2.5 kb upstream from the start of the hTERT open reading frame to just after the 40 first intron within the coding region, with the initiating Met codon of the hTERT open reading frame changed to Leu. Plasmid pGRN175 was made by APA1(Klenow blunt)-SRF1 digestion and religation of pGRN150 to delete most of the Genomic sequence upstream of hTERT. This makes a promoter/reporter plasmid that uses 204 nucleotides of hTERT upstream sequences (from position -36 to -117). Plasmid pGRN176 was made by

PML1-SRF1 religation of pGRN150 to delete most of the hTERT upstream sequences. This makes a promoter/reporter plasmid that uses 204 nucleotides of hTERT upstream sequences (from position -36 to -239).

5 Levels of secreted placental alkaline phosphatase (SEAP) activity were detected using the chemiluminescent substrate CSPDTM (ClonTech). SEAP activity detected in the culture medium was found to be directly proportional to changes in intracellular concentrations of SEAP mRNA. The pGRN148 and pGRN150 plasmids (hTERT promoter-reporter) and the pSEAP2 plasmid (positive control, containing the SV40 early promoter and enhancer) were transfected into test cell lines. pGRN148 and pGRN150 constructs drove SEAP expression as efficiently as the pSEAP2 in immortal (tumor-derived) cell lines. Only the pSEAP2 control gave detectable activity in mortal cells.

10 The ability of the hTERT promoter to specifically drive the expression of the thymidine kinase (*tk*) gene in tumor cells was tested using a variety of constructs: One construct, designated pGRN266, contains an EcoRI-Fsel PCR fragment with the *tk* gene cloned into the EcoRI-Fsel sites of pGRN263. pGRN263, containing approximately 2.5 kb of hTERT promoter sequence, is similar to pGRN150, but contains a neomycin gene as selection marker. pGRN267 contains an EcoRI-Fsel PCR fragment with the *tk* gene cloned into the 15 EcoRI-Fsel sites of pGRN264. pGRN264, containing approximately 210 bp of hTERT promoter sequence, is similar to pGRN176, but contains a neomycin gene as selection marker. pGRN268 contains an EcoRI-XbaI PCR fragment with the *tk* gene cloned into the EcoRI-XbaI (unmethylated) sites of pGRN265. pGRN265, containing approximately 90 bp of hTERT promoter sequence, is similar to pGRN175, but contains a neomycin gene as selection marker.

20 These hTERT promoter/*tk* constructs, pGRN266, pGRN267 and pGRN268, were re-introduced into mammalian cells and *tk*/+ stable clones (and/or mass populations) were selected. Ganciclovir treatment in vitro of the *tk*/+ cells resulted in selective destruction of all tumor lines tested, including 143B, 293, HT1080, Bxpc-3', DAOY and NIH3T3. Ganciclovir treatment had no effect on normal BJ cells.

25 **Figure 5** is a map of the TPAC adenovector pGRN376. It was made by cloning the NOT1-BAMH1 fragment from pGRN267 into the NOT1-BGL2 sites of pAdBN (Quantum Biotech). The 7185 bp vector comprises the herpes simplex thymidine kinase (TK) gene under control of the medium-length hTERT promoter sequence.

**Example 10: Transduction of hES cells with a thymidine kinase construct**

30 These experiments test the effect of the pGRN376 vector described in the preceding Example on hES cells. The vector contains the herpes virus thymidine kinase gene under control of the telomerase reverse transcriptase promoter. Expression of the thymidine kinase gene in cells should render them susceptible to toxicity from the prodrug ganciclovir.

35 Undifferentiated H1 cells were plated into 24 well plates (1 confluent well of a 6 well plate split into 24 wells of a 24 well plate). After 48 h, some wells were infected with the TPAC vector at an MOI of 30 or 100. Four h after addition of the viral vector, medium was exchanged for new mouse embryonic fibroblast conditioned medium (mEF-CM); some wells received medium supplemented with 30  $\mu$ M ganciclovir (GCV). Cells exposed to GCV were re-fed with mEF-CM containing 30  $\mu$ M GCV daily for 4 days. On days 2, 3, and 4 after the initiation of GCV treatment, wells were harvested and analyzed by flow cytometry to assess changes 40 in 1) total cell number and 2) cell viability (measured by PI exclusion).

Figure 6 shows the results of this experiment. No change in total cell number was detected at MOI of 30 in the absence of GCV; but there was some decrease at MOI of 100 in absence of GCV starting at 48 h. Evidence for toxicity of GCV alone was detected: wells receiving GCV alone contained approximately 55% as

many cells as the control wells on day 2, diminishing to 40% by day 4. Wells receiving GRN376 at MOIs of 30 or 100 cultured in the presence of GCV showed identical results: by day 2, these wells contained 18% of the cells contained in the control wells, while at days 3 and 4 these wells contained 6% and 8% of the cells in the control wells.

5 Slight toxicity was seen at MOI of 100 at day 4 in the absence of GCV (50% cells in ES gate vs. 83% for the control cells). Some toxicity of GCV alone was observed at d2, 75% cells in ES gate (vs. 85% control); at day 3, 68% (vs. 82% control); at day 4, 50% (vs. 65% control). Wells receiving GRN376 at MOIs of 30 or 100 cultured in the presence of GCV showed similar results: by day 2, these wells contained 24-28% cells in the ES gate, at day 3 they contained 19-22% cells in the ES gate, and at d4 these wells contained 12% cells in the ES gate. Thus, GRN376 plus GCV is effective at killing undifferentiated hES cells at an MOI as low as 30.

#### *Titration Experiment*

10 Undifferentiated H1 cells were plated into 24 well plates (1 confluent well of a 6 well plate split into 24 wells of a 24 well plate). After 48 h, some wells were infected with pGRN376 at an MOI of 30. Four h after 15 addition of the viral vector, medium was exchanged for new mEF-CM; some wells received medium supplemented with 5, 10, 20, 30, or 40  $\mu$ M ganciclovir (GCV). Cells exposed to GCV were re-fed with mEF-CM containing GCV daily for 2 days. On day 2 after the initiation of GCV treatment, wells were harvested and analyzed by flow cytometry to assess changes in total cell number, and cell viability (measured by PI exclusion).

20 Figure 7 shows the results of this experiment. ~20  $\mu$ M GCV was optimal under the conditions tested.

#### *Comparison of different hES lines*

25 Undifferentiated hES of lines designated H1 and H7 cells were plated into 24 well plates (1 confluent well of a 6 well plate split into 24 wells of a 24 well plate). After 48 h, some wells were infected with pGRN376 at an MOI of 30. Four h after addition of the viral vector, medium was exchanged for new mEF-CM; some wells received medium supplemented with 20  $\mu$ M GCV. Cells exposed to GCV were re-fed with mEF-CM containing GCV daily for 3 days. On day 4 after the initiation of GCV treatment, wells were harvested and analyzed by flow cytometry to assess changes in total cell number.

30 Figure 8 shows the results. The total cell number demonstrated decreases in cell number for both lines after TPAC vector treatment. H7 showed less toxicity induced by GCV alone than did H1. Thus, different hES cell lines respond to the TPAC vector. In subsequent studies, the H9 cell line was also found to be highly sensitive to GCV after TPAC vector treatment.

#### Example 11: Selection of differentiated cells

35 In this experiment, hES cells were treated with retinoic acid (RA) or dimethyl sulfoxide (DMSO), and then analyzed for hTERT and OCT-4 expression after treating with TPAC.

Undifferentiated H1 cells were plated into 24 well plates (1 confluent well of a 6 well plate split into 24 wells of a 24 well plate). 24 h later, some wells were re-fed with mEF-CM containing either 500 nM RA or 0.5% DMSO; wells were re-fed with medium supplemented with RA or DMSO for the remainder of the experiment. 40 After 7 days of treatment with RA or DMSO, cells were infected with GRN376 at an MOI of 30.

Four h after addition of the viral vector, medium was exchanged for new mEF-CM (plus RA or DMSO where appropriate); some wells also received medium supplemented with 20  $\mu$ M ganciclovir (GCV). Cells exposed to GCV were re-fed with mEF-CM containing GCV daily for 3 days. On day 3 after the initiation of

GCV treatment, wells were harvested and analyzed by flow cytometry to assess changes in total cell number. Additional wells were used in an effort to culture out any remaining undifferentiated stem cells; the medium of these wells was changed to mEF-CM (without RA, DMSO, or GCV). Cells were refed with mEF-CM every day for 7 days, then harvested for isolation of RNA. These samples were analyzed by quantitative RT-PCR for the expression of hTERT and OCT-4.

Figure 9 shows that the cell number decreased after TPAC treatment. After 7 days of drug pretreatment followed by TPAC plus GCV, all wells contained similar cell numbers. During the attempt to culture out surviving stem cells, the wells became confluent with highly differentiated appearing cells; no undifferentiated hES cells were obvious. Wells containing cells that had been pre-treated with RA were distinct in appearance from the cells either pre-treated with unadulterated mEF-CM or treated with mEF-CM plus DMSO. RT-PCR analysis (Lower Panel, non-quantitative, 35 cycles) showed that the surviving cells from the mEF-CM or DMSO-treated wells had no detectable OCT-4 expression, while 2 out of 4 RA-pre-treated samples presented very weak OCT-4 PCR products.

Thus, no detectable undifferentiated cells survive TPAC treatment followed by subsequent culture of wells grown in mEF-CM or mEF-CM plus DMSO. RA pre-treatment leads to detection of low levels of OCT-4 in the surviving cells. It is not clear whether this reflects persistence of undifferentiated stem cells or induction of another cell type that expresses OCT-4.

Example 12: Stable stem cell lines containing the TPAC construct:

To facilitate creation of stable cell lines genetically altered with the hTERT promoter/thymidine kinase construct, plasmid pGRN376 (Example 9) was modified to delete most of the adenovirus sequence. The plasmid was digested with Stu I and Not I, followed by blunting and re-ligation. The remaining vector contained the hTERT promoter/thymidine kinase construct, preceded by the transcription blocking sequence to prevent promotion of *tk* gene expression by promoter sequences upstream from the integration site in the genome. The modified vector was designated pGRN376mod.

pGRN376 – adenoviral TPAC vector

Ad5	TRM	pTERT 216 bp	HSV TK	SV40 polyA
-----	-----	-----------------	--------	---------------

pGRN376mod – TPAC plasmid vector

	TRM	pTERT 216 bp	HSV TK	SV40 polyA
--	-----	-----------------	--------	---------------

30

Cultures of the H9 hES cell line were split 1:4 using PBS containing 0.5 mM EDTA, as described earlier, and plated in feeder-free culture in 6-well plates. Twenty-four hrs after plating, cells were cotransfected with 2 µg GRN376mod plus 0.5 µg of a plasmid encoding neomycin phosphotransferase, using FuGENE™-6 as described above. Medium containing 200 µg/mL geneticin was added 48 h after transfection to select out transfected cells. After 7-10 days in geneticin-containing medium, 103 individual colonies were picked from the wells and individually plated in 24-well plates, which were then expanded by culturing for ~7 days. Ninety individual clones were screened for sensitivity to the pro-drug ganciclovir at a concentration of 30 µM. Ten

clones were identified in which essentially all the undifferentiated cells died within 1-3 days of culture with ganciclovir, leaving only remnant cells that had differentiated outside the main colony.

5 In another experiment, the H1 line of hES cells (passage 59) was split 1:6 into Matrigel®-coated 24 well plates in standard hES cell medium (day 0; 1 ml/well, MEF conditioned medium with 4 ng/mL bFGF). The medium was exchanged with new standard medium on the following day. On day 3, the medium was removed and replaced with either 200 µL/well standard medium (mock transfection), or pGRN376 virus at MOI 100, diluted in 200 µL/well standard hES medium. After 4 h, the medium was removed from all wells and replaced with 1 mg/mL standard hES medium with or without 30 µM ganciclovir. The wells were exchanged with fresh medium (with or without 30 µM ganciclovir) on each of the next three days.

10 **Figure 10** is a micrograph of the cells on day 6. In wells transduced with control vector (Panel A), hES colonies formed colonies with normal characteristics. In wells transduced with pGRN376 virus and then treated with ganciclovir (Panel B), most or all ES cell colonies are gone and only differentiated cells remain. The TPAC-treated wells contained 8-fold fewer cells than the control wells.

15 **Example 13: Further Characterization of Stable TPAC Embryonic Stem Cell Lines**

TPAC stable clones were derived by co-transfection of pGRN376mod and pGK-neo plasmids into the hES cell line H9 grown in mEF conditioned media with basic FGF on growth factor reduced Matrigel® coated plates.

20 In one experiment, the H9 line (p 80) was passaged 6 times using 0.5 mM EDTA prior to transfection. 2 µg of pGRN376m plasmid and 0.5 µg of pGK-neo plasmid were used for transfection of each well of a 6 well plate of ES cells, using a 3:2 ratio of Fugene™ (a lipid-based transfection facilitator) to DNA. The cells were transfected 24 hours after seeding, and G418 selection was initiated 24 h post-transfection. 101 G418-resistant colonies were picked using collagenase. Clones from cells transfected only with pGK-neo were isolated as controls for co-transfection.

25 Individual colonies were expanded using 0.5 mM EDTA for primary and secondary GCV screening. Primary screen with 30 µM GCV (weeks 1 and 2) identified 10 GCV-sensitive clones and 20 partially GCV-sensitive clones. Secondary screen with 30 µM GCV (weeks 3 and 4) confirmed 9 GCV-sensitive clones, including those designated H9-376m-18, H9-376m-77, and H9-376m-62. Following secondary GCV screening, cells were expanded using 0.5 mM EDTA into larger cultures and then passaged using collagenase.

30 In a second experiment, the H9 line (p 24) was again initially passed using 0.5 mM EDTA, and then transfected as before. Sixty two G418-resistant co-transfected colonies were picked using collagenase on day 0. Primary screen with 30 µM GCV (days 20, 22, and 26) identified one GCV-sensitive clone and four partially GCV-sensitive clones. Following primary GCV screening, cells were expanded using 0.5 mM EDTA into larger cultures and gradually returned to standard collagenase passaging. Secondary screen with 30 µM GCV (day 35 57) confirmed one GCV-sensitive clones (designated H9-376m-6).

The GCV-sensitive clones from each of these experiments were subject to further selection in culture with G418, to determine their stability. Clones designated H9-376m-18 and H9-376m-77 showed G418 resistance that was not stable. Clones designated H9-376m-62, H9-376m-6, and H9-pGK-neo-1 were G418 resistant.

40 **Figure 11 (top)** shows sensitivity of the stable TPAC lines to ganciclovir (GCV). Each cell line was exposed to decreasing amount of GCV to determine lowest concentration of GCV required to produce complete killing of undifferentiated ES cells with the least amount of toxicity. Concentrations as low as 0.5 µM were determined to kill undifferentiated ES cells similar to 30 µM, but with a significantly lower toxicity.

Figure 11 (bottom) shows sensitivity of the TPAC lines to a different prodrug, (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). Although a significant decrease on cell counts was observed with all BVDU concentrations tested, ES cell killing was not actually observed. The number of cells present even at high concentrations of BVDU is not reduced to the level of the blank control.

5 To verify expression of HSV-TK in stable TPAC ES cell lines, RT PCR was performed on undifferentiated cells from H9-376m-6, H9-376m-62 and H9-pGK-neo-1 cultures using HSV-TK or OCT-4 specific primers. TK expression was detected in H9-376m-6 and H9-376m-62 samples and not in H9-pGK-neo samples at high concentrations of RNA, while OCT-4 expression was detected in all samples.

10 Example 14: Promoter specificity for undifferentiated cells

To determine hTERT promoter specificity on in the stable TPAC clones, GCV sensitivity was determined after differentiation of each TPAC clone and the pGK-neo control clone.

15 Undifferentiated cells were seeded in growth factor reduced Matrigel® coated plates with KO DMEM plus 20% Hyclone FBS without bFGF (differentiation conditions). Cultures were maintained in differentiation conditions for 7 days, passaged and placed in the differentiation conditions for additional 4 days. Following this treatment, cultures contained few if any undifferentiated cells (assessed by morphology). At this point, 30 µM GCV was added to the differentiated cultures for 4 days.

20 There was no sensitivity to GCV observed in differentiated cultures obtained from the TPAC cell lines H9-376m-6, H9-376m-62, H9-376m-18, or H9-376m-77; or from the transfection control line H9-pGKneo. Thus, the hTERT promoter in the integrated construct has the appropriate specificity for turning on the TK effector gene only in undifferentiated cells.

Example 15: ES marker expression in undifferentiated TPAC cell lines

25 Expression of ES markers on stable TPAC ES cell lines was determined by flow cytometry. Cells were harvested from confluent cultures using 0.5 mM EDTA and incubated with monoclonal antibodies against human SSEA-4, SSEA-1, Tra-1-60, Tra-1-81, CD9, AC133, and appropriate fluorochrome-conjugated secondary antibodies. Level of expression was determined using FACSCalibur™. Appropriate isotype matched negative controls and viability assessment were used to determine the level of non-specific binding.

Table 2: Markers on Parental hES cells and Stable TPAC Lines

Phenotypic marker	H9 p 35	H9-376m-62 p 80+15	H9 p 25	H9-pGK-neo p 24+16	H9-376m-6 p 24+19	H9-376m-62 p 80+27
SSEA4 +	92*	100	64	37	91	98
SSEA1 +	1	0	0	0	0	0
Tra-1-60 +	98	99	89	89	86	90
Tra-1-81 +	96	99	82	88	77	97
CD9 +	88	95	81	98	91	99
AC133 +	90	81	72	78	68	70

\*% of live cells expressing markers.

H9-376m-6, H9-376m-62 and H9-pGK-neo-1 cell lines have expression of all tested ES markers at the levels comparable to those of untransfected H9 cell line.

Example 16: Ability of TPAC cell lines to undergo appropriate differentiation

5 H9-376m-6, H9-376m-62, H9-376m-77, H9-376m-18 and H9-pGK-neo-1 were tested for their ability to generate cells from three embryonic germ lineages. Embryoid bodies (EBs) were established from each cell line and cultured in suspension with KO DMEM and 20 % Hyclone FBS. Following 4 day culture, EBs were plated on gelatin-coated chamber slides and allowed to grow for additional 8-10 days. Cultures were scored for the presence of beating cells and stained for the presence of  $\beta$ -tubulin, AFP, muscle-specific actin and cardiac

10 troponin I positive cells.

Figure 12 shows representative fluorescence micrographs of immunocytochemistry. Results were as follows.

- H9-376m-18 p 80+20 was able to generate large embryoid bodies (1 experiment). Beating areas (consistent with cardiomyocyte-lineage cells) were observed. Muscle-Specific Actin +++;  $\alpha$ -fetoprotein +++;  $\beta$ -tubulin +++; cardiac troponin I +.
- H9-376m-77 p 80+16 generated only small embryoid bodies (1 experiment). No beating areas were observed. Muscle-Specific Actin +;  $\alpha$ -fetoprotein + $\beta$ -tubulin - (none detected); cardiac troponin I -.
- H9-376m-62 p 80+16, p 80+20, p 80+21, p 80+24 (4 experiments) were capable of generating only small embryoid bodies. No beating areas were observed. Muscle-Specific Actin ++;  $\alpha$ -fetoprotein +;  $\beta$ -tubulin +; cardiac troponin I -.
- H9-376m-6 p 24+12, p 24+13, p 24+21 (3 experiments) were able to generate large embryoid bodies. Many beating areas were observed in all experiments. Muscle-Specific Actin ++;  $\alpha$ -fetoprotein ++;  $\beta$ -tubulin +++; cardiac troponin I +.
- H9-pGK-neo-1 p 24+9, p 24+10, p 24+13 (3 experiments) were able to generate large embryoid bodies. Beating areas were observed in 2 out of 3 experiments.  $\beta$ -tubulin +++; cardiac troponin I +; Muscle-Specific Actin +++;  $\alpha$ -fetoprotein ++.

The results of Examples 13-16 show that at least three of the stem cell lines containing the telomerase promoter driven thymidine kinase gene are capable of differentiating into cells of each of the three germ layers.

30. Differentiated cells from these lines contain an important stop-gap against residual or reemerging undifferentiated cells. Ganciclovir at a concentration as low as 2.5  $\mu$ M kills virtually all such modified undifferentiated ES cells within ~4 days.

SEQUENCE DATA**TABLE 3: Sequences listed in this Disclosure**

SEQ. ID NO:	Designation	Reference
1	Lambda clone designated λGφ5 (ATCC Accession No. 98505)  Contains human Telomerase Reverse Transcriptase (hTERT) genomic insert (residues 44-15375). The ATG translation initiation site begins at residue 13545.	GenBank Accession AF121948 International Patent Publication WO 00/46355.
2	Herpes simplex virus type 1 thymidine kinase and 3KBL gene sequence	GenBank Accession J02224 See also McKnight et al., Nucleic Acids Res. 8:5949 (1980); Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441 (1981)
3	Herpes simplex virus type 1 thymidine kinase and 3KBL amino acid sequence	(supra)
4 - 7	Probes and Primers	(Artificial Sequences)

5 *It will be recognized that the compositions and procedures provided in the description  
can be effectively modified by those skilled in the art without departing from  
the spirit of the invention embodied in the claims that follow.*

CLAIMS

What is claimed as the invention is:

1. A population of cells differentiated from primate pluripotent stem (pPS) cells cultured *ex vivo*, which is essentially free of undifferentiated cells.
2. The cell population of claim 1, wherein the cells contain a nucleic acid molecule comprising the structure P-X, wherein:  
X is a nucleic acid sequence encoding a product that is lethal to a cell in which it is expressed, or renders a cell in which it is expressed susceptible to a lethal effect of an external agent; and  
P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells.
3. A primate pluripotent stem (pPS) cell containing a nucleic acid molecule comprising the structure P-X, wherein:  
X is a nucleic acid sequence that is lethal to a cell in which it is expressed, or renders a cell in which it is expressed susceptible to a lethal effect of an external agent; and  
P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells.
4. The cell or cell population of claim 2 or 3, wherein X encodes a toxin, or a protein that induces or mediates apoptosis.
5. The cell or cell population of claim 2 or 3, wherein X encodes an enzyme that converts a prodrug to a compound that is lethal to a cell in which X is expressed.
6. The cell or cell population of claim 5, wherein X encodes a thymidine kinase.
7. The cell or cell population of claims 2-6, wherein P-X is an introduced heterologous molecule.
8. The cell or cell population of claims 2-6, wherein P is an endogenous transcriptional control element.
9. The cell or cell population of claims 2-6, wherein P is an OCT-4 promoter, or a promoter of telomerase reverse transcriptase (TERT).
10. The cell or cell population of any preceding claim, wherein the stem cell(s) are human embryonic stem (hES) cells.

11. A method of producing a population of differentiated cells, comprising
  - a) providing a cell population comprising undifferentiated stem cells that contain a nucleic acid molecule comprising the structure P-X, wherein X is a nucleic acid sequence encoding a product that is lethal to a cell in which it is expressed, or renders a cell in which it is expressed susceptible to a lethal effect of an external agent, and P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells; and
  - b) causing at least some undifferentiated cells in the population to differentiate.
12. The method of claim 11, further comprising combining the cell population with the external agent.
13. A method of depleting a cell population of undifferentiated stem cells, comprising genetically altering undifferentiated stem cells in the population so that they contain a nucleic acid molecule comprising the structure P-X, wherein X is a nucleic acid sequence encoding a product that is lethal to a cell in which it is expressed, and P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells.
14. The method of claims 11-13, wherein X encodes a toxin, or a protein that induces or mediates apoptosis.
15. A method of depleting a cell population of undifferentiated stem cells, comprising:
  - a) genetically altering undifferentiated stem cells in the population so that they contain a nucleic acid molecule comprising the structure P-X, wherein X renders a cell in which it is expressed susceptible to a lethal effect of an external agent, and P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells; and
  - b) depleting undifferentiated cells from the population by combining the cells with the external agent.
16. The method of claim 11, 12 or 15, wherein X encodes an enzyme that converts a prodrug to a compound that is lethal to a cell in which X is expressed.
17. The method of claim 16, wherein X encodes a thymidine kinase.
18. The method of claim 16 or 17, wherein the external agent is ganciclovir.
19. The method of claims 11-18, wherein P-X is an introduced heterologous molecule.
20. The method of claims 11-18, wherein P is an endogenous transcriptional control element.
21. The method of claims 11-20, wherein the cell population is genetically altered such that X is transiently expressed in undifferentiated cells in the population.
22. The method of claims 11-20, wherein P-X is inherited by progeny of cells in the population, becoming expressed in undifferentiated progeny.

23. The method of claims 11-22, wherein P is an OCT-4 promoter, or a promoter of telomerase reverse transcriptase (TERT).
24. The method of claims 11-23, wherein the nucleic acid molecule contains the structure P-X-Y, wherein Y is a drug resistance gene.
25. The method of claims 11-24, wherein the stem cells are human embryonic stem (hES) cells.
26. A population of differentiated cells obtained according to the method of any of claims 11-25.
27. The cell or cell population according to any of claims 1-10 or claim 26, which is a population of neuronal cells, astrocytes, oligodendrocytes, hepatocytes, cardiomyocytes, osteoblasts, or their committed precursor cells.
28. A pharmaceutical preparation for human or animal surgery or therapy, comprising the cell or cell population according to any of claims 1-10 or 26-27.
29. Use of a prodrug in the preparation of a medicament for depleting undifferentiated stem cells in a human or animal body,  
wherein the undifferentiated stem cells comprise the structure P-X, where:  
X is a nucleic acid sequence encoding a product that converts the prodrug to a compound that is lethal to the undifferentiated stem cells; and  
P is a transcriptional control element that causes X to be preferentially expressed in undifferentiated cells.
30. The use according to claim 29, wherein the prodrug is ganciclovir.

Figure 1





Figure 2




Figure 3







Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9






Figure 10

A.



B.




**Figure 11**

Figure 12A





Figure 12B



SEQUENCE LISTING

<110> Geron Corporation  
 Gold, Joseph  
 Lebkowski, Jane  
 <120> Differentiated Cells Suitable for Human Therapy  
 <130> 096/200  
 <140> [to be assigned]  
 <141> 2001-11-26  
 <150> 09/783,203  
 <151> 2001-02-13  
 <150> 60/253,443  
 <151> 2000-11-27  
 <150> 60/253,357  
 <151> 2000-11-27  
 <160> 7  
 <170> PatentIn version 3.0  
 <210> 1  
 <211> 15418  
 <212> DNA  
 <213> Homo sapiens  
 <400> 1

gcggccgcga	gctctatac	gactcaat	agggcgtcga	ctcgatcaat	ggaagatgag	60
gcattgccga	agaaaaagatt	aatggatttg	aacacacagc	aacagaaaact	acatgaagtg	120
aaacacagga	aaaaaaagat	aaagaaacgc	aaagaaaaagg	gcatcagtga	gcttcagcag	180
aagtccatc	ggccttacat	atgtgtaa	agaggccctg	taggagcaga	ggcaggggga	240
aaatacttta	agaaataatg	tctaaaagtt	tttcaaatat	gaggaaaaac	ataaaaaccac	300
agatccaatg	agtcataa	acaaaagcac	aagaaacagg	aagaattaa	aagttatatc	360
acatgtcaat	tgcgtaaaac	cgcacaaaaa	gagaatatct	taaggtatc	agaggaaaaq	420
agatataatg	caggccaa	aacaatgaaa	acaatacaga	tttctttag	gaaacacaag	480
acaaaaagaca	ttttttaaa	ccaaaaggaa	aaaaaatgtt	acattaaaat	gttttttacc	540
caactgaaat	atatttcaaa	acatattttt	ggccaggctt	ggtggtctac	acctgtatc	600
ccaggactt	gggaggccaa	gggtgggtgg	tcgcctttaagg	tcaggagttc	gagaccagcc	660
tggccatatt	agcgaaaaac	catctgtact	aaaaacacaa	aaatttagtgc	ggtgtggta	720
catatgtctt	taatcccagg	tactcaggag	gctaaaggcag	gagaatttgc	tgaactggga	780
ggcagaggtt	gtgagccaag	attgcaccag	tgcactccag	ccttgggtgc	agagtgaac	840
tccatctcaa	aaacaaacaa	acaaaataca	tatataaaaa	tatatatgc	cataatatata	900
catatataaa	tatataataca	catatataaa	tctatataca	tatataatata	tatacacata	960
tataaatcta	tatataatata	tataatata	taatataat	acatataata	atataatatacat	1020
atataatataat	acatataataa	atataatata	aaatatacat	atataatata	acatataataaa	1080
atatacatat	ataatataat	acatataataa	atatacatat	ataatataat	atataatataat	1140
aaatataat	atatacaat	atataatataat	atatacatat	ataatgtat	atacgtatata	1200
acatataatataat	ataatataat	aaaaaaactt	ttggctggc	acccatccaa	atctcatggc	1260
acatataatgt	ctatgtttaa	cctccaaataa	aaaaacatat	aacagataca	ccaaaaataaa	1320
aaaccaataa	attaaatcat	gccaccagaa	gaaattacct	tcactaaaag	gaacacagga	1380
aggaaagaaa	gaagggaaag	aagaccatga	aacaaccaga	aaacaaacaa	caaaacagca	1440
ggagtaattc	ctgactttatc	aataataatg	ctgggtgtaa	atggactaaa	ctctccaaatc	1500
aaaagacatc	gatggctgta	atggacgaaa	aaaacaagac	tcaataatct	gttgcttaca	1560
agaatataatc	tcaatataaa	aggacacat	agactgaaaa	taaaaggaa	aaaaaatatt	1620
ctatgcaat	ggaaacccaa	aaaagaacag	aactagctac	acttataatca	gacaaaatag	1680
atttcaagac	aaaaagtaca	aaaagagaca	aagtaattat	ataataatata	agcaaaaaagaa	1740
tataacaat	gtgaaatttat	atgcgcctaa	cactggacac	cccagatata	tacagcaaat	1800
attatttagaa	ctaaaggag	agagagatcc	ccatataata	atagctggag	acttcacccc	1860
gcttttagca	ttggacagat	catccagaca	gaaaatcaac	caaaaaatgt	gacttaatct	1920
ataatataat	acaatatgtac	ctaaattgtat	tttacaagac	atttcatcca	gtagttgcag	1980
aatatgcatt	ttttcctcag	catatgtatc	atttctcaagg	atagaccata	tattaggc	2040
cagaacaca	cattaaaaat	tcaaaaaaaat	tgagccaggc	atgtggctt	atgcttgc	2100
ttacagcact	ttggggaggg	tgaggtggga	ggatgttttgc	agtagcagg	tttgagacca	2160
gcttggcaa	aatagtgaga	ccctgtctt	acaaactttt	tttttaattt	agccaggcat	2220
agtgggtgt	gcctgttagtc	ccagctactt	aggaggctga	agtggggagga	tcacttgagc	2280

ccaagagttc aaggctacgg tgagccatga ttgcaacacc acacaccgc ctttgtgaca 2340  
gaatgagacc ctgtctcaaa aaaaaaaaaa aaaattgaaa taatataaag catttctct 2400  
ggccacatgt gaacaaacc agaaatcaac aacaaggaga atttggaaa ctataacaaac 2460  
acatgaaaat taaaacatat acttctgaat aaccatgtg tcaataga aattaaaagaa 2520  
gaaattgaa aattttttaa acaaaatgt aacggaaaca taacctctca aaaaaacacgg 2580  
tatacagcaa aagcagtgtc aagaaggaaat tttatagcta taagcagcta catcaaaaaa 2640  
gtagaaaagc caggcgcagt ggctcatgcc tgtaatccca gcacttggg agggcaaggc 2700  
gggcagatcg cctgagggtca ggagtctcg accagcctga ccaacacaca gaaaccttgc 2760  
cgctactaa aatacacaat tagctggca tggttggcaca tgcctgtat cccagctact 2820  
cgggaggctg aggccaggata accgcttggc cccaggagggt ggagggtcg tggagccggg 2880  
attgcgcctat tggactcccg ctgggttaac aagagtaaa cctgtctca agaaaaaaaaa 2940  
aaaagttagaa aaacttaaaa atacaaccta atgatgcacc ttaaagaact agaaaagcaa 3000  
gagcaacta aaccctaaat tggttaaaga aaagaataa taaaagatcg acaaaaaataa 3060  
aattgaaatcg aagataaca atacaaaatgg tcaacaaaat taaaattgtt tttttgaaa 3120  
agataaaacaa aattgacaaa cttttggcca gactaaagaa aagggaaaga agacccaaat 3180  
aaataaagtgc agagatgaaa aagagacat tacaactgtat accacagaaa ttcaaggat 3240  
caactagggc tactatgagc aactgtacat taataaattg aaaaacctcg aaaaatataa 3300  
taaattctctt gatgcataca acctaccaag attgaacat taaagatcg acaaaaaataa 3360  
cagaccaata acaataatgg gattaaggcc atacaaaatgg tttttgttgc aagagaagc 3420  
ccaggacccatc atggcttcc tgcgttggat tccaaatcat taaaagaaaaa atgatccca 3480  
atccactacta aacttcttc aaaaatagag gaaagaatac ttcaaaactc attctacatg 3540  
gccagtattt ccctgattcc aaaaccagac aaaaacacat caaaaacaaa caaacaaaaaa 3600  
aacagaaaaga aagaaaacta caggccataa tccctgtatga atactgatcat aaaaatctc 3660  
aacaacaaacat tagcaacaa aattaaacaa caccctcgaa agatcattca ttgtgtatcaa 3720  
gtgggattt ttcccgaggat ggaaggatgt tccaaatcat gcaataatcat caatgtata 3780  
catcatccca acaaaatggat tgcataaaac tatatgatta tttcacttta tgcaaaaaaa 3840  
gcatttgata aatttctgca cccttcatga taaaacccct caaaaaccca ggtatacaag 3900  
aaacatacag gccaggcaca gtggctcaca cctgcgtatcc cagactctg ggaggccaaag 3960  
gtgggatgtat tgccttggcc caggaggatgg agactactgtt gggcaacaaa atgagacctg 4020  
gtcttacaaaactt taaaatttgc caggatgtatgg tccaaatcat gcaataatcat caatgtata 4080  
gcttagtctgg aggctggagg tggagaatac cttaaaggctt ggggtcgatgg gctcgtatgt 4140  
gccccatgtat gtcactgtt cttcaggcata gacaacagaa caagacccca ctgaaataaga 4200  
agaaggagaa ggagaaggaa gaaaggaggaa agaaggaggaa aggaggagaa ggaggaggatg 4260  
gaggagaagt ggaaggggaa ggggaaggaa aagggaaaga aagggaaaca tatitcaaca 4320  
taataaaaggc cttatatgc agacccgggt agtattatgc gggaaactgt aaagcccttc 4380  
ctcttacatgtatgg tggaaaatgtt caaggccccca ctttcaccatc tttgttccaaatcat 4440  
gaagtcttagt cttagacaaat cagataaagag aaagaataa aaggcatcca aactggaaag 4500  
gaagaagtca aattatctt tttgcagatg atatgtatctt atatctggaa aagacttaag 4560  
acaccactaa aaaaactatgc gagctgtatgg tttgttccatc aggatcataaa atcaatgtac 4620  
aaaattatcatgtatgg ttttttttttcaatcatc gcaaaacatc tggaaaagaaa acaaaaaaaag 4680  
cagctacaaa taaaatttttcaatcatc gcaaaacatc tggaaaagaaa acaaaaaaaag tcttccat 4740  
gaaaactata aataatttgc aaaaagaaattt gaagaggggca caaaaaaaga aaagatattc 4800  
catgttctata gattggaaaga ataaatactgt taaaatgttc catactaccc aaacaaattt 4860  
acaacaaatcc tgcacccatc taaaatgttc taatgtccatc cttccacagaa atagaagaaa 4920  
caatttctataatgg ttttttttttcaatcatc gcaaaacatc tggaaaagaaa acaaaaaaaag 4980  
aaaaaaacaaa aacttggaaatc atccatcatc tggaaaatgtt ctttccatc tttgttccat 5040  
taacccaaacatc tacatgttgc tggcataaaa acagatgaga catggaccag aggaacagaa 5100  
tagagaatcc agaaacaaatcc ccatgtatcc acagtgtactt ctttccatc tttgttccat 5160  
agaacataactt ttttttttttcaatcatc gcaaaacatc tggaaaagaaa aacgggttccat 5220  
ccatcatgtca aataacataatgg ttttttttttcaatcatc gcaaaacatc tttgttccat 5280  
atggatgaaaatcc ggttttttttcaatcatc ttttttttttcaatcatc gcaaaacatc tttgttccat 5340  
agaaaactcttc ctttttttttcaatcatc ttttttttttcaatcatc gcaaaacatc tttgttccat 5400  
ggcaacccaaatcc gcaaaacatc ttttttttttcaatcatc gcaaaacatc tttgttccat 5460  
aaaggaaacatc atcaacaaatcc ttttttttttcaatcatc gcaaaacatc tttgttccat 5520  
cttttttttcaatcatc ttttttttttcaatcatc gcaaaacatc tttgttccat 5580  
gaaaaacacccatc taataacatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 5640  
aaaaataatgtt atcaacatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 5700  
cagagaaatgtt caaaatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 5760  
tatttttttcaatcatc ttttttttttcaatcatc gcaaaacatc tttgttccat 5820  
acactgttgc tggaaatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 5880  
aaaatcaatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 5940  
aaaaatcaatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6000  
ggaatctgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6060  
agccaaggtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6120  
gtgcacatcatc acaatggatgtt actacgcac ttttttttttcaatcatc gcaaaacatc tttgttccat 6180  
aacagcatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6240  
ggggcacttgc ttttttttttcaatcatc gcaaaacatc tttgttccat 6300  
tttttttttcatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6360  
aggagaatgtt ttttttttttcaatcatc gcaaaacatc tttgttccat 6420  
tgtatgtttt ttttttttttcaatcatc gcaaaacatc tttgttccat 6480  
aaaatgttcaatcatc ttttttttttcaatcatc gcaaaacatc tttgttccat 6540  
ctgttgcacatcatc acaatggatgtt actacgcac ttttttttttcaatcatc gcaaaacatc tttgttccat 6600

tctactaaaat	tagccaggcg	tgggtggcaca	tacctgttagt	cccaactact	6660
caggaggctg	agacaggaga	attgctgaa	cctggggagc	ggaggttgca	6720
atcatgccac	tgcactgcag	cctgggtgac	agagaagac	tccatctcaa	6780
aaaaaaaaaaa	gattaaaatt	gtatttta	tgtaccgtat	aaatataac	6840
tagaagttaa	aaataaaac	aattaaaaa	ggttaataac	cacttaatct	6900
caatgtatgt	ggggttctta	gcttctgaag	aagtaaaagt	tatggccacg	6960
tgtgaggagg	gaacagtgg	agtactgtt	gttagacgt	catactctt	7020
taattttaac	caaagacagg	ctgggagaag	ttaaagagc	attctataag	7080
actgcaacta	atgtgaaaag	gtatctcta	ttaattacca	ataattacag	7140
aatcgagctg	cagaattggc	acatctgatc	acaccgtct	ctcattcacg	7200
tcttgtgtc	ttggagattt	tcgattgtgt	gttcgtt	gtttaaactt	7260
aatctgaaa	cgaaaaatgg	tgtgattt	ctccagaaga	attagagtac	7320
gcagggtggct	ctgtggacct	gaggccactt	aatcttcaag	ggttcaatgg	7380
gtgcaaggca	gaggcctgat	gaccggagga	caggaaagct	cgatggggaa	7440
gaaggctgcc	tcgtgggtga	gcagegcata	aagtgcctt	attacgcctt	7500
gctctggata	ccatctggaa	aaggccggca	gcgggaatgc	aaggagttag	7560
ctcaaaccca	ggccagcagc	tatggccccc	accggggct	gtgcagagg	7620
aaggcacctc	gaagtatggc	ttaatcttt	tttccatctt	aaggcgtgac	7680
tctgaggaaa	gcttgatgtt	gttgccttct	ttaaaacaga	aagtcatgga	7740
tcaaggaaa	accagacgca	cgtctcggt	tcatttatct	tccctcttct	7800
gccctcgccg	tttctgtatcg	ggacagagtg	acccctgtgg	agcttctcg	7860
gaggaccctc	ttgcaaaggg	cttccacagac	cccccctg	gagagaggag	7920
gcttaataac	aaactgggat	gtggctgggg	gcccggacgg	acggccggat	7980
aattccatga	gttaatccat	ctttccaca	tccgaatgg	tttggatttt	8040
tttcttaaat	ttcatcaaat	aacattcagg	agtgcagaaa	tccaaaggcg	8100
actgagctat	gtttgccaag	gttccaaggac	ttaataaacc	tgttcaggg	8160
cctaagtact	ttttattttt	tttcataagg	tggcttaggg	tgcagggaa	8220
gagaggactg	ggccgcagg	ctatgagcac	gcaaggccca	ccggggagag	8280
ctggggaggct	gacagcgac	ccactgcgg	tccctccctg	gagctgccc	8340
gccaaggccg	ccacgtcg	tgtactcg	gacccttac	cggttccctg	8400
cactaacc	ggaagtccag	gagctctgaa	ccctgtggaa	cgacatgac	8460
ctgctccct	gggtgggtca	agggtaatga	agtgggtg	aggaaatggc	8520
acacgactt	gctgtatggg	accgttccct	ccatcattat	tcatcttcac	8580
tgaatgat	cagaacttcc	ttcgggtgt	acaagccat	acaactca	8640
cacttta	ctaggccccac	agagcacggc	ccacacccct	gatataattaa	8700
gagatgaggc	tgctttcagc	caccaggctg	gggtgacaa	agcggctgaa	8760
ctctagacta	gtagaccctg	gcaggactc	ccccagattc	tagggctgg	8820
ccgaggccgc	cattgtccct	ggagacttag	cctgggtg	caactgggg	8880
ctccacaccc	tccgtccca	ggccctgat	tctccagcg	tctctaaac	8940
ccgtgttcca	gcgtactgt	ctcaccgtc	ccactgttc	ttgtctcag	9000
gcacggttcc	tccatcatg	gggtgtctgt	tcccttcccc	aacactcaca	9060
ggaggagatt	ctgcccctcc	cagactggct	cctctgagcc	tgaaccctgc	9120
cgatcgagg	ttctggcgct	cggtgcacg	ctgaccatca	tttccaggcg	9180
cctgtcatcg	ggccggccct	ttctgggtgt	tcttctgtt	ttctgtctt	9240
agtcgtgt	gttctgttcc	gtctgggtct	cggggggtttt	ataggcatag	9300
tggggggcca	gggcgtctt	gggaaatgca	acattttggg	gtgaaagtag	9360
cctcacctag	gttccacgggc	acaggctgg	ggatggagcc	cccccacgg	9420
cctctccag	cattttctg	ccccccctcc	tcttggacac	agatggcg	9480
cactaagcat	cctttccca	aaagacccag	cattggacatt	tgcctccac	9540
ccctggaaat	tcacgtact	acgcacatca	tgtacacact	ccctgtccac	9600
gctgttttat	ttaatagct	acaaaggcagg	gaaatccctg	ctaaaatgtc	9660
ctgggtttaa	aaacgggtcc	atccgcacgg	tggacagttc	ctcacgttg	9720
gcccgttata	aaagctcg	gcatctcaag	gaaattacgc	tttccacaa	9780
catggatata	gtacgcacaa	tgtcaaaaa	gaaaatattt	caccccatgg	9840
gttgggggtt	taaggacggt	ggggggcagca	gtctggggct	actgcacgc	9900
aaggcagg	cctgttctg	atggatattg	ctcagttatg	ggagactaa	9960
tggggatggg	gaaacccgga	gctgtgcca	tcttgcctat	gcccgtgt	10020
ataatgtct	agagatgccc	acgtccct	ggtttttttt	cttggggcagg	10080
gccccggggc	cttgcaggat	gtgtatctcg	tgaggaccct	gagggttggg	10140
actacctgca	ggccccaaaa	gtatccagg	gttctggga	agaggccggc	10200
gaggggggca	gctcaggac	gatggaggca	gtcagtctg	ggctggaaaag	10260
cctcgagccc	aggcctgca	ggccctccag	aagctggaa	aagcggggaa	10320
acggaggctg	caggaggaa	gcacggctgg	cccttagccc	accaggcccc	10380
tccggccctcc	gtgccccat	aggcgactcg	cggttccctt	ctagcatgaa	10440
atttgacaa	gcaacaggaa	acccatgcac	tgtgaatcta	ggatttttc	10500
tttacagaaaa	catccaagga	caggctgaa	gtgcctccgg	gcaaggccag	10560
agtgtttttt	tttagctatt	ttatttttt	tacttactt	ctgagacaga	10620
tgttgcgg	gttggagtgc	agcggcatga	tcttgcctca	ctgcacccct	10680
gttcaagca	tttctgtgc	tcagccctcc	aagttagctgg	gatttcaggc	10740
acacccggct	aattttgtat	tttttagtaga	gatgggtttt	caccatgttg	10800
tctcaaaatc	ctgacccatcg	gtgtatccccc	accctcagcc	tcccaaaatc	10860
aggcatgagc	cactgcaccc	ggccattttta	accattttaa	aacttccctg	10920

acaccactg	gtaaggagtt	catggagttc	aatttccctt	ttactcagga	gttaccctcc	10980
tttgatattt	tctgttaattc	ttcgttagact	ggggatacac	cgctcttga	catattcaca	11040
gtttctgtga	ccacccgtta	tcccatggga	cccaactgcag	gggcagctgg	gaggctgcag	11100
gcttcaggtc	ccagtgggtt	tgccatctgc	cagttagaaac	ctgtatgtaga	atcaggggcgc	11160
gagtgtggac	actgtccatg	atctcaatgt	ctcagtgtgt	gctgaacat	gtagaaattta	11220
aagtccatcc	ctcttactct	actggatttgc	agcccccttc	ctatcccccc	ccaggggcag	11280
aggagttcct	ctcactcctg	tggaggaagg	aatgatactt	tgttattttt	cactgctgg	11340
actgaatcca	ctgtttcatt	tgttgggtt	tttggatgtt	tttggagggc	ggtttcaactc	11400
tttgttgcct	ggctgggg	agtcaatgg	ccgcgttgc	gtttactgc	gcctctgcct	11460
cccagggtca	agtatttctc	ctgttccgc	ctcccatgtt	gggggattta	caggcacccg	11520
ccacccatgc	cagttcaattt	tttttatttt	tagtagagac	gggggttggg	gtggggttca	11580
ccatgttgc	caggctggc	tcgaaacttct	gacccatgt	gatccaccc	cctctgcctc	11640
ctaaagtgt	gggattacag	gtgtgagcc	ccatgcccag	ctcagaattt	actctgtttt	11700
gaaacatctg	ggctgggtt	aggaaatgtca	ccccactcaa	gtttgtgtt	gttttaagcc	11760
aatgatagaa	tttttttttt	tttggatggaa	cacttgc	tttttacact	gtgtacta	11820
agacatcatc	agtttccaa	agacacacacta	actgcaccc	taataactggg	gtgttctctg	11880
ggtattcagcg	atcttcattt	aatggccggg	ggcggttctt	cgccatgcac	atgggtttaa	11940
ttactccagc	ataatcttct	gttccattt	tttctcttcc	ctttaatttt	atttgtttt	12000
ctatgttgc	ttcttgcag	agaaccaggta	taactacaa	ctttaatttt	gttggaaacaa	12060
atttttccaa	ccggcccttt	ggccatgttgg	cagagacat	tcacaaacac	agccctttaa	12120
aaaggcttag	ggatcactaa	ggggatttct	agaagagcga	cccgtaatcc	taagtattta	12180
caagacgagg	ctaaacctca	gcgagcgtga	cagcccgagg	agggtgcgag	gcctgttcaa	12240
atgctagctc	cataaataaa	gaaatttcc	ccggcgtt	tttgcgttgc	gaaagggttac	12300
attttttttt	gcgtttgtt	gcatttcgt	gttttgcgc	ctcgttgc	gcatccctgc	12360
aaggccctgg	gagaccggc	agtttctcgc	cccttagatc	caaaatttgc	caaccggag	12420
tctggattcc	tggggagttcc	tcagctgtcc	tgccgttgc	ccggggcccc	agggtcgag	12480
gggaccagg	ggccgtgtgg	tttctactgt	gggctggaa	tcgggctcc	tagctctgc	12540
gtccgaggct	tggagccagg	tcgttgcgg	ccggaggctgc	cttcaccc	gtgcgggcgg	12600
gatgtgacca	gatgttggcc	tcatctgc	gacagatgc	ccggggccag	ggtcaaggcc	12660
gtttgtgtgt	gtgtggggc	ccccgttgc	ggcccgagg	agccgttgc	tccatttccc	12720
acccttctc	gacgggaccc	ccccgggtgg	tgatataacag	attttgggtt	gtttgttcat	12780
gggtggggacc	cctcgccg	tgagaacatg	caaagagaaa	tgacggggcc	gtgtcaaggaa	12840
gccaagtcg	ccccggaaatg	tttgcaggag	gcactccgg	aggttccgg	tgcccttcc	12900
ggggagcaatg	cgtccctcg	tctgttccca	ccgcgttca	cgccctcc	tcctccctt	12960
cacgtccgc	atttgcgttgc	ccccggggcc	gacgcccc	gttccggac	ggaggcagcc	13020
ctgggtctcc	ggatcaggcc	agccggccaa	gggtcgccgc	acgcaccc	tccaggggcc	13080
tccacatcat	ggcccttccc	tcgggttacc	ccacgccta	ggccgttcc	acctcttcc	13140
gctggggccc	tcgttgcgt	ccctgcaccc	ttggagcgc	agccgtcgc	gggcggggaa	13200
gcgcggccca	gaccggccgg	tccggccgg	ccgcgttgc	tttgcggcc	aggccgggtt	13260
cccaatggat	tcgcgggc	agacggccag	gaccgcgtt	ccacatgttgc	ggaggggactg	13320
ggggaccgg	cacccgttcc	ggcccttcc	tttccagtc	ccgccttcc	gcgcggaccc	13380
cgccccgtcc	cgacccctcc	cggttcccc	gcccagcccc	ctccggggcc	tccagcccc	13440
tcccttctt	tcccgcc	ccgccttcc	tcgcgttgc	gatgttcc	cagcgttgc	13500
tcctgtgtc	cacgttggaa	tccctggcc	ccgcaccc	ccgcgttgc	ccgcgttcccc	13560
gctgcgac	cgtgtgttcc	tcgtgtgc	gcccactcc	ccgcgttgc	ccgcgttgc	13620
cgttcggtc	cgcccttgggg	ccccagggtt	ggccgttgc	tgatgttgc	ccgcgttgc	13680
cttttcgtgc	gtgtgtggcc	cagtgcgttgc	ttgtgtgtcc	ctgggacgc	ccggccggcccc	13740
ccggccggccc	tccttcgtcc	cagtgtggcc	ccccgggggtt	ccgcgttcc	ctgggggttgc	13800
ggggccggcc	ggggaaaccc	cgacgtgc	agagcagcc	aggcgactca	gggcgttcc	13860
cccgccgttgc	tccgttgc	aggagttgt	ggcccccgttgc	ctgcgttgc	tgtgtcgag	13920
cgccgcgttgc	aacgtgttgc	ccttcgttgc	ccgcgttgc	tgatgttgc	ccggccggcccc	13980
ccccggggcc	tttccacca	ccgtgcgttgc	tttccaccc	tttccaccc	ccgcaccc	14040
gcggggggac	ggggcggtgg	gggtgtgttgc	ccgcgttgc	gggcgttgc	tgctgtttca	14100
ccctgtgtcc	tcgttgcgt	gggtgtgttgc	gggcgttcc	ccgcgttcc	accagggtgt	14160
ccggccggcc	tcgttgcgt	gggtgtgttgc	ccgcgttcc	ccgcgttcc	cacacgttgc	14220
tggaccccg	aggcggttgc	tttccaccc	ccgttgcgttgc	tgatgttgc	ggggggggcc	14280
ggtccccctg	ggccgtcc	ccccgggttgc	gaggaggcc	ggggggcgttgc	ccagccgaag	14340
tctgtgttgc	cccaagggcc	ccaggcgttgc	ccgttgc	ccgcgttcc	ggacggccgt	14400
tggccagggtt	tccctggccc	accggccgttgc	ccgcgttcc	ccgcgttcc	ggacggccgt	14460
tgtgtgttgc	ccttcgttgc	gggtgtgttgc	ccgcgttcc	ccgcgttcc	ccaggccgttgc	14520
cacccgcac	tccacccat	ccgttgcgttgc	ccacttgc	ccgcgttcc	ccaggccgttgc	14580
gcggccacca	cgtcccttgg	acacgccttgc	tcccccgttgc	tgatgttgc	ccaaagactt	14640
ccttcacttc	tcaggcgaca	aggaggat	ccgcgttcc	tttccactt	gtctctgt	14700
gcccacgttgc	acttgcgttgc	gggggttgc	ggagaccatc	tttccactt	ccaggccgttgc	14760
gatgtccagg	acttgcgttgc	gggtgtgttgc	ccgcgttcc	tttccactt	aaatgcgttgc	14820
cctgtttctg	gagctgttgc	ggaaaccacgc	ccgcgttcc	tttccactt	tttccactt	14880
gcactgtcc	ctgcgttgc	ccgttgcgttgc	ccgcgttcc	tttccactt	tttccactt	14940
ccaggccgttgc	gtgtgtgttgc	ccaggccgttgc	ccgcgttcc	ccaggccgttgc	tttccactt	15000
gctcccgcc	cacacgttgc	ccttgcgttgc	ccgcgttcc	ccaggccgttgc	ccctgcgttgc	15060
gctgtgttgc	ccaggccgttgc	gggggttgc	ccacaacaa	ccgcgttcc	tcaggaaacac	15120
caagaatgtt	atctcccttgc	ggaaacccatgc	ccagcttgc	ccgcgttcc	tgacgttgc	15180
gatgagcg	cggttgcgttgc	ccggacttgc	ccaggccgttgc	ccaggccgttgc	tttccactt	15240

cgaggccc	ggccccagag	ctgaatgcag	tagggctca	aaaaaggggg	caggcagagc	15300
cctggtc	ctgttccat	cgtaacgtgg	gcacacgtgg	ctttcgctc	aggacgtcg	15360
gtggacacgg	tgatcgagtc	gactccctt	agtgagggtt	aattgagtc	gcggccgc	15418

<210> 2  
 <211> 2403  
 <212> DNA  
 <213> Herpes simplex virus type 1

<400> 2

gggtcctagg	ctccatgggg	accgtatacg	tggacaggct	ctggagcatc	gcacgactgc	60
gtgatattac	cgaggacatt	ctgcgggacg	agccgggtca	cgccgctcg	ggagcgtccg	120
ttggcgaca	aaccacggg	cgggcacag	gtacactatc	tgtcaccac	gagcgcgagg	180
gactcgaggg	gcttcaggga	cggtcgccgc	tgttcatcc	ccgtggccgg	ttgctcgctg	240
ttgttgcgg	tgccccggg	agaatataat	ttgatgtct	ttagttctat	gtgacacaa	300
acccccc	gcgttctgtc	atggcgaat	tcaaacacgc	agatgcagtc	ggggcgccgc	360
ggtcccggt	ccacttcgc	tattaagggt	acgcgtgtgg	cctcaaacac	cgagcgaccc	420
tgcagcg	cgcttaacag	cgtaaacgc	tgccgcaga	tcttgggtgc	tgaaaactcc	480
cgccatctt	tgcaagcgc	tgcttgcgg	tcgtatggc	tgcgtacccc	tgccatcaac	540
acgcgtctgc	gttgcaccag	gtctgcgcgtt	ctcgccggca	tagcaacccg	cgtacggcgt	600
tgcgcctcg	ccggcagcaa	gaagccacgg	aagtccgcct	ggagcagaaa	atgcccacgc	660
tactcggggt	ttatatacag	ggtcctc	ggatggggaa	aaccaccc	acgcaactgc	720
ttgtggccct	gggttcgcgc	gacgatatac	tctacgtacc	cgagccatgc	acttactggc	780
aggtgtcg	ggcttcccgag	acaatgcga	acatctacac	cacaacac	cgcctcgacc	840
agggtagat	atccggccggg	gacgcggcg	ttgtaatgac	aagcggccag	ataacaatgg	900
gcatgc	tgcgtgacc	gacgcgttc	tggctctca	tgcgggggg	gaggctggga	960
gttcacatgc	cccgcccccc	gcctc	tcatcttcg	ccgcattccc	atgcggcccc	1020
tcctgtgtc	cccgccgcg	cgataccctt	tggcgcgc	gaccccccag	gccgtctgg	1080
cgttcgtgc	cctcatcccg	ccgacattgc	ccggcaca	catctgttg	ggggcccttc	1140
cggaggacag	acacatgcac	cgcc	ccgcgcgag	ccccggcgag	cggcttgacc	1200
tggctatgc	ggccgcgtt	cgccgcgt	acgggcgtct	tgccat	gtgcggat	1260
tgcaggcg	cggtcgtgg	tggaggatt	ggggacgt	tgcgggacg	ccgcgtccgc	1320
cccgaggatc	cgagccccag	agcaacgcgg	gcccacgacc	ccatatcg	gacacgttat	1380
ttaccctgtt	tcgggcccc	gagttctgtgg	cccccaacgg	cgacctgtat	aacgttttg	1440
cctggccctt	ggacgtcttg	gccaacgc	tccgtccat	gacgtctt	atccgtgatt	1500
acgaccaatc	gcccgcggc	tgcgggacg	cctgtgc	acttacccc	gggatgttgc	1560
agacccacgt	caccacccca	ggctccat	cgacgtat	cgacccgt	cgcacgttt	1620
cccgaggat	ggggaggatc	aactaaaca	cgaaaggaga	caatacccg	aggaacccgc	1680
gctatgcgg	caataaaag	acagaataaa	acgcacgggt	ttgggtgt	ttgttcataa	1740
acgcggggtt	cgtcccgagg	gctggactc	tgtcgatacc	ccacccgag	cccatgggg	1800
ccaaatacgc	cgcgttctt	ccctttcccc	accccaaccc	ccaaatcc	gtgaaggccc	1860
aggctcgca	gccaacgtcg	ggccggcaag	ccgcgcata	ccacggccc	cgtgggttag	1920
ggatgggttc	ccccatgttt	aatgggttat	gtgtgtggg	gttattttt	ttggggtgtt	1980
cgtggggta	gttccacgac	tggactgac	agacagacc	atgggtttt	atgggtctgg	2040
gcattggacc	catgtactgg	cgcgacacga	acacggcg	tctgtgtct	ccaaacaccc	2100
ccgacccccc	aaaaccaccc	cgccgat	tggccgc	ggacgaacta	aacctgacta	2160
cgccatctt	gccttctt	cgctgttt	aggacgcgtt	tttttttta	ttgttccacca	2220
cgcccgagg	tccgcggac	ccccccgc	tgttttacat	ctcgaagacc	tacctactcg	2280
gcccggcccc	gaacgcgac	ctgccc	ccatcacgg	cgacccgacc	gcccagcc	2340
cccccccggt	cgccccctt	aagggtctt	tgcaacatcc	aaccgcctt	gtgttgcgt	2400
gtt						2403

<210> 3  
 <211> 376  
 <212> PRT  
 <213> Herpes simplex virus type 1

<400> 3

Met	Ala	Ser	Tyr	Pro	Cys	His	Gln	His	Ala	Ser	Ala	Phe	Asp	Gln	Ala
1				5				10					15		
Ala	Arg	Ser	Arg	Gly	His	Ser	Asn	Arg	Arg	Thr	Ala	Leu	Arg	Pro	Arg
					20			25					30		
Arg	Gln	Gln	Glu	Ala	Thr	Glu	Val	Arg	Leu	Glu	Gln	Lys	Met	Pro	Thr
					35			40					45		
Leu	Leu	Arg	Val	Tyr	Ile	Asp	Gly	Pro	His	Gly	Met	Gly	Lys	Thr	Thr
					50			55					60		
Thr	Thr	Gln	Leu	Leu	Val	Ala	Leu	Gly	Ser	Arg	Asp	Asp	Ile	Val	Tyr
					65			70					75		80
Val	Pro	Glu	Pro	Met	Thr	Tyr	Trp	Gln	Val	Leu	Gly	Ala	Ser	Glu	Thr
					85			90					95		

Ile Ala Asn Ile Tyr Thr Thr Gln His Arg Leu Asp Gln Gly Glu Ile  
 100 105 110  
 Ser Ala Gly Asp Ala Ala Val Val Met Thr Ser Ala Gln Ile Thr Met  
 115 120 125  
 Gly Met Pro Tyr Ala Val Thr Asp Ala Val Leu Ala Pro His Val Gly  
 130 135 140  
 Gly Glu Ala Gly Ser Ser His Ala Pro Pro Ala Leu Thr Leu Ile  
 145 150 155 160  
 Phe Asp Arg His Pro Ile Ala Ala Leu Leu Cys Tyr Pro Ala Ala Arg  
 165 170 175  
 Tyr Leu Met Gly Ser Met Thr Pro Gln Ala Val Leu Ala Phe Val Ala  
 180 185 190  
 Leu Ile Pro Pro Thr Leu Pro Gly Thr Asn Ile Val Leu Gly Ala Leu  
 195 200 205  
 Pro Glu Asp Arg His Ile Asp Arg Leu Ala Lys Arg Gln Arg Pro Gly  
 210 215 220  
 Glu Arg Leu Asp Leu Ala Met Leu Ala Ala Ile Arg Arg Val Tyr Gly  
 225 230 235 240  
 Leu Leu Ala Asn Thr Val Arg Tyr Leu Gln Gly Gly Ser Trp Trp  
 245 250 255  
 Glu Asp Trp Gly Gln Leu Ser Gly Thr Ala Val Pro Pro Gln Gly Ala  
 260 265 270  
 Glu Pro Gln Ser Asn Ala Gly Pro Arg Pro His Ile Gly Asp Thr Leu  
 275 280 285  
 Phe Thr Leu Phe Arg Ala Pro Glu Leu Leu Ala Pro Asn Gly Asp Leu  
 290 295 300  
 Tyr Asn Val Phe Ala Trp Ala Leu Asp Val Leu Ala Lys Arg Leu Arg  
 305 310 315 320  
 Pro Met His Val Phe Ile Leu Asp Tyr Asp Gln Ser Pro Ala Gly Cys  
 325 330 335  
 Arg Asp Ala Leu Leu Gln Leu Thr Ser Gly Met Val Gln Thr His Val  
 340 345 350  
 Thr Thr Pro Gly Ser Ile Pro Thr Ile Cys Asp Leu Ala Arg Thr Phe  
 355 360 365  
 Ala Arg Glu Met Gly Glu Ala Asn  
 370 375

<210> 4  
<211> 25  
<212> DNA  
<213> Artificial PCR primer sequence  
<400> 4  
cttgctgcag aagtgggtgg aggaa 25  
  
<210> 5  
<211> 21  
<212> DNA  
<213> Artificial PCR primer sequence  
<400> 5  
ctgcagtgtg ggtttcgggc a 21  
  
<210> 6  
<211> 20  
<212> DNA  
<213> Artificial PCR primer sequence  
<400> 6  
cggaagagtgc tctggagcaa 20  
  
<210> 7  
<211> 19  
<212> DNA  
<213> Artificial PCR primer sequence  
<400> 7  
ggatgaagcg gagtctgga 19

**THIS PAGE BLANK (USPTO)**

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)